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Synthesis of 5-/8- Halogenated or Ethynylated Lipophilic 
Nucleobases as Potential Synthetic Intermediates for 
Supramolecular Chemistry 
Nerea Bilbao,[a] Violeta Vázquez-González,[a] M. Teresa Aranda,[a] and David González-Rodríguez*[a] 
Abstract: A series of lipophilic nucleobases that are substituted at the 
5- (pyrimidines) or 8-position (purines) with either a halogen atom or 
a terminal triple bond have been synthesized. The sequences and 
reactions studied in this work, which mainly comprise halogenation, 
alkylation, Sonogashira coupling, and trimethylsilylacetylene 
deprotection, have been carefully optimized in order to reach the final 
compounds in the most straightforward, convenient way and with the 
maximum purity and yield. These compounds include cytosine, 
isocytosine and uracil as pyrimidine heterocycles, and guanine, 
isoguanine, and 2-aminoadenine as complementary purine bases. 
Variability was introduced at the N-1/N-9 positions of these 
pyrimidine/purine nucleobases, which were functionalized with alkyl 
or benzyl groups, as well as with protected amine or carboxylic acid 
substituents. The molecules prepared constitute a useful collection of 
synthetic intermediates in the field of chemical self-assembly.  
Introduction 
The design of chemical moieties having specific hydrogen-
bonding patterns has been exploited by supramolecular chemists 
to make interact one or more molecular components and thus 
create well-defined assemblies with diverse functions.[1] 
Hydrogen-bonding is employed here as a highly selective and 
directional noncovalent interaction, whose strength can be tuned 
as a function of the chemical nature of donor and acceptor 
functions, as well as on their number and sequence in a particular 
molecular fragment.[2] These moieties can be seen as 
“supramolecular directors” that are able to couple specific 
molecular components in a geometrically defined arrangement, 
where in many cases hydrogen-bonding interactions cooperate 
with additional weak non-covalent forces such as π-π stacking, 
solvophobic or Coulombic interactions. [3] 
Among these supramolecular hydrogen-bonding units, 
naturally occurring DNA bases and synthetic nucleobase 
analogues are of particular relevance.[4],[5] Besides, nucleobase 
derivatives play a crucial role in nature and have been found as 
clinically useful molecules with diverse biological activities. An 
example of interest is constituted by N-9 substituted guanines, 
such as acyclovir, because of their potential antiviral activity.[6] For 
these reasons, the development of efficient and reliable synthetic 
routes to modified nucleobases as versatile building blocks in self-
assembly can be of great importance and utility to the 
supramolecular chemist.[7],[8] 
Here, we describe the synthesis of a series of chemically-
modified lipophilic natural and non-natural nucleobase derivatives 
(Figure 1) that are equipped with either an halogen atom or an 
ethynyl group at the 5-position (for the pyrimidines) or at the 8-
position (in the case of the purines). Pyrimidine nucleobases 
comprise cytosine (C), uridine (U), and isocytosine (iC), whereas 
the purines prepared in this work are guanine (G), 2,6-
diaminopurine or 2-aminoadenine (DAP; hereafter abbreviated as 
A), and isoguanine (iG). Together, these complementary 
nucleobases constitute a useful collection of synthetic 
intermediates for supramolecular chemistry. On one hand, the 
halogenated position can be employed to attach these units to 
functional molecules with the aim of driving their self-assembly via 
a large battery of metal-catalyzed cross-coupling reactions.[9] On 
the other, the rich and useful reactivity of the terminal triple bond, 
either through Sonogashira couplings or “click” cycloaddition 
reactions, make these six nucleobases convenient “synthons” for 
the preparation of complex organized systems.[10] These 
heterocycles have been further substituted with lipophilic alkyl or 
benzyl groups or with protected amines and carboxylic acids at 
the N-1 (pyrimidines) or N-9 (purines). As opposed to related 
nucleosides,[8] where the bulky ribose unit attached at these 
position limits aggregation, these simple and planar groups may 
help in producing hierarchical assemblies where hydrogen-
bonding is combined with other non-covalent interactions acting 
in orthogonal directions, such as π-π stacking with other 
molecules or with planar substrates. 
Figure 1. General structure of the pyrimidine (C, U, iC) and purine (G, A, iG) 
derivatives targeted in this work. 
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Results and Discussion 
As shown in Figure 1, our target nucleobases present common 
functional groups, such as the halogen atom or the ethynyl group 
at the 5-position of pyrimidines and the 8-position of purines, as 
well as variable substituents, such as the diverse lipophilic groups 
at the 1-position of pyrimidines and the 9-position of purines. 
Therefore, the ideal, most convergent synthetic route to these 
derivatives would comprise three consecutive steps: 1. 
Halogenation (bromination or iodination); 2. Palladium-catalyzed 
Sonogashira coupling[9] with trimethylsilylacetylene (TMSA), 
followed by trimethylsilyl (TMS) deprotection and; 3. Nucleophilic 
substitution with the corresponding alkylating reagent.[11] Since 
the variability in our compounds is introduced at the level of the 
alkyl substituents, a lower number of products would need to be 
synthesized using this sequence. However, as will be explained 
below for each nucleobase, different problems arose during 
synthesis that made us deviate from this optimal route. Many 
intermediates were unreactive in some conditions and/or 
displayed very low solubility to be properly purified. The 
sequences and reactions described in this work have been 
therefore carefully optimized in order to reach the final 
compounds in the most straightforward and convenient way and 
with the maximum purity and overall yield.  
Synthesis of pyrimidines. With the aim of reaching the most 
convergent route, iodination of the pyrimidine heterocycles was 
selected as the first reaction in the synthetic schemes towards 
lipophilic C, U and iC derivatives. The incorporation of iodine was 
chosen instead of bromine due to the higher reactivity of 
iodoarenes in metal-catalyzed cross-coupling reactions. Different 
iodination agents and protocols, such as iodine/iodic acid 
(I2/HIO3), iodine/periodic acid (I2/H5IO6), N-iodosuccinimide (NIS), 
or iodine monochloride (ICl), were essayed. Only the best options 
for each substrate are reported here. Next, the Sonogashira 
coupling in different conditions was attempted in each 5-
iodopyrimidine. However, none of them (C, U or iC) was reactive. 
We believe that N-1 unsubstituted pyrimidines can deactivate the 
catalytic palladium species thorough chelation via one of their 
different tautomeric forms, as has been suggested for other 
nucleobase derivatives.[12] 5-iodo-substituted pyrimidines were 
instead subjected first to an alkylation reaction which is, in most 
cases, quite selective for the N-1 position. The Sonogashira 
reaction was performed on these alkylated iodopyrimidines, 
leading in all cases to excellent yields of coupled products. Finally, 
the TMS protecting group was cleaved in the presence of 
tetrabutylammonium fluoride (TBAF).  
Cytosine (Scheme 1). A total of six 5-iodocytosine and 5-
ethynylcytosine derivatives were synthesized, each of them 
having different alkyl or benzyl groups. Iodination of commercial 
cytosine (Scheme 1a) was carried out in the presence of I2 and 
HIO3.[13] In these conditions, 5-iodocytosine (C3) was obtained in 
close to quantitative yields by neutralization and straightforward 
filtration and washing. This product was then subjected to an 
alkylation reaction in the presence of the corresponding 
alkyl/benzyl halide. These reactions are typically carried out in the 
presence of cesium or potassium carbonates but, in the case of 
our iodoalkanes and benzyl halides, the use of these bases did 
not afford good yields. Instead, the more soluble Bu4NOH base in 
methanol[14] was used to deprotonate C3 and produce C2Alk10, 
C2Alk6, C2Alk2, C2Bn2, and C2Bn3 in acceptable yields. 1-Alkyl-5-
iodocytosines were then transformed into the final 5-ethynyl 
derivatives using standard Sonogashira-TMS deprotection 
methods.[15] 
 
Scheme 1. Synthetic routes to 5-iodo- and 5-ethynyl-cytosines using the (a) 
halogenation-alkylation or (b) alkylation-halogenation sequence. 
We also tested the inverted reaction order, that is, alkylation 
of cytosine followed by halogenation (Scheme 1b). Besides being 
less convergent, this alternative route presented other types of 
drawbacks. First, the isolation of the halogenated products was 
more tedious and produced lower yields. Second, the presence of 
the bulky iodine atom at the C5 position in C3 was proven 
effective in directing alkylation selectively at the N-1 position.[16] 
For instance, when carrying out the alkylation reaction with ethyl 
iodide directly onto commercial cytosine, a triply alkylated 
byproduct was also obtained, having ethyl chains at the N-1 
position but also in the amino group. Finally, performing the 
halogenation after the alkylation reaction is not compatible with 
the benzyl-substituted derivatives, since they comprise electron-
rich aryl groups that would give rise to mixtures of halogenated 
products.  
Uridine (Scheme 2). The route to the uridine derivatives 
started directly from commercial 5-iodouridine, a compound that 
can also obtained in excellent yields from uridine.[17] 5-iodouridine 
was alkylated in the presence of Cs2CO3, which was proven to be 
slightly more efficient than K2CO3 because of its better solubility 
in organic solvents. The yields of U2Alk10 and U2Alk6 were not very 
satisfactory, although they are in the same range of those 
 
 
 
 
 
 
reported on similar alkylation reactions with uridine derivatives.[18] 
One of the reasons for these relatively low yields is the additional 
formation of N-3-substituted products and the corresponding 
dialkylated products, identified by 1H NMR and MS, which 
compete with alkylation at N-1. Finally, 1-Alkyl-5-iodouracils were 
then converted to the corresponding 5-ethynyl derivatives via 
cross-coupling reaction with TMSA. Traces of deiodinated 
products were detected in this last reaction.  
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Scheme 2. Optimized synthetic route to 5-iodo- and 5-ethynyl-uracils. 
Isocytosine (Scheme 3). The nonnatural isocytosine analog 
iCAlk2 was also prepared following the halogenation-alkylation 
sequence. In this case, iodination was carried out in the presence 
of N-iodosuccinimide (NIS),[19] since it afforded better results than 
other methods. Alkylation was then performed using the same 
procedure as with the cytosine derivatives. The base was 
equipped with a simple ethyl group for subsequent sublimation 
studies under ultrahigh vacuum. This reaction led as well to the 
N-3-substituted product in minor amounts, which could be 
separated by chromatography from the target N-1-alkylated 
derivative. Product iCAlk2 is the only one in this work that was not 
transformed into the corresponding 5-ethynyl derivative.  
 
Scheme 3. Synthetic route to 5-iodo-isocytosine iCAlk2. 
Synthesis of purines. The optimized route to 8-halogenated and 
8-ethynylated purines followed a different synthetic sequence to 
that used with the pyrimidines. We were of course interested in 
achieving the most convergent path by introducing the 
halogenation step[20] as soon as possible in the sequence, as we 
have shown with the pyrimidines. However, although this was 
accomplished in some cases, the early introduction of the halogen 
atom resulted in a series of secondary problems during 
subsequent reactions that reduced the overall yield. Hence, the 
alkylation reaction was preferably carried out as the first step in 
the routes to guanine, 2-aminoadenine and isoguanine 
derivatives, despite the higher number of products that needed to 
be synthesized. Then, the alkylated products were either 
brominated or iodinated. The preparation of 8-iodopurines was 
obviously preferred because of their higher reactivity in 
subsequent palladium-catalyzed couplings, so their synthesis 
was optimized and studied in more detail using different iodination 
methods. The iodine substituent could be introduced either by 
electrophilic aromatic substitution in the presence of diverse 
reagents (vide supra) or by deprotonation at the 8-position 
followed by quenching with iodine. The first method, together with 
NBS bromination, was not compatible with the benzyl groups, 
since they bear electron-rich aromatic rings that are more 
activated towards electrophilic substitution than the purine ring, 
as we found out during our tests (see below). As in the case of 
the pyrimidines, the Sonogashira reaction was left as the last step 
in the sequence to 8-ethynylpurines. This reaction, as will be 
explained below, required in some instances previous functional 
group protection of the purine heterocycles. Similarly to the 
pyrimidine bases, all our attempts to perform this palladium-
catalyzed coupling after halogenation and before alkylation were 
unsuccessful, probably because of deactivation of the catalytic 
species due to a higher metal-coordination ability of N-9 
unsubstituted derivatives.  
Guanine (Schemes 4 and 5). The development of an efficient 
synthetic route to 8-ethynyl lipophilic guanines (G1Alk10, G1Alk2, 
G1Bn2, G1Bn3) turned out to be, with a big difference, the most 
complex task in this work and considerable effort was dedicated 
to this mission. There are several reasons for this. The low 
solubility of guanine or 2-amino-6-hydroxypurine in different 
solvents is one of them. Among all the nucleobases, guanine 
exhibits the most rich supramolecular chemistry[21],[22] and often 
self-associate in solution to form highly insoluble products or 
viscous gels. Also, guanine, and in general purines, are 
constituted by a mixture of tautomers that can lead to different 
isomers in the alkylation reactions. The most common of them are 
the N-7 and N-9 alkylated products, which are sometimes difficult 
to separate.[23] But probably the most important reason is the 
requirement to protect or mask the carbonyl group before 
palladium-catalyzed cross-couplings. As a matter of fact, the low 
reactivity of the guanine heterocyle in metal-mediated oxidative 
addition processes has been reported.[8],[12],[24] The low oxidation 
potential of this base or its ability to coordinate organometallic 
catalytic species are cited among the causes that would explain 
such lack of reactivity.[12] Conversion to different functionalized 
derivatives like 6-alkoxy-,[8],[24],[25] or 6-halogenopurines, which, at 
the same time, may exhibit a higher selectivity in the alkylation 
reaction, is an alternative. Unfortunately, the use of these starting 
reagents involve higher costs and an increase in the number of 
reaction steps, which results in poorer overall yields. Furthermore, 
previous methods reported in the literature for the conversion of 
2-amino-6-chloropurine into guanine use vigorous acidic or basic 
conditions that are not compatible with sensitive functional groups.  
We essayed first the use of 2-amino-6-chloropurine as the 
starting reagent and we evaluated different routes and sequences 
from this commercial derivative (Scheme 4). Our initial idea was 
to perform the whole three-step reaction sequence directly on this 
kind of derivatives. Since our attempts to halogenate this 
substrate under different conditions were unsuccessful, we 
started the route by alkylating 2-amino-6-chloropurine with 
diverse iodoalkanes, to yield G5Alk10 and G5Alk2, and with the 
corresponding benzyl bromide, to afford G5Bn3.[26] Whereas the 
benzyl halide led mainly to a single N-9 alkylation product,[27] 1-
iododecane or 1-iodoethane, presumably due to their lower steric 
 
 
 
 
 
 
hindrance, produced mixtures of N-7 and N-9 substituted 
products in an approximate 1:4 ratio, although the overall yields 
were still very satisfactory.  
Next, we tested halogenation on G5Alk10. Only NBS-mediated 
bromination worked properly in our hands. However, treatment of 
this substrate in the presence of NBS unexpectedly afforded a 
mixture of brominated products, mainly including our target 2-
amino-8-bromo-6-chloropurine and 2-amino-6,8-dibromopurine, 
in which the 6-chloro atom was replaced by bromine. 
Unfortunately, this mixture could not be separated and the use of 
other conditions did not avoid the formation of this dibrominated 
secondary product. Then, the mixture was subjected to a 
Sonogashira coupling to see if one of these 6- or 8-positions 
reacted selectively or if the products could be separated at the 
last step by chromatography. Despite all our attempts under 
different conditions and palladium catalysts, both positions 
seemed to be equally reactive and our target compound could not 
be separated from the mixture of ethynylated products. On the 
other hand, the hydrolysis of the mixture of brominated products 
in acidic conditions[28] led to mixtures of 8- and 6-oxopurines.  
 
Scheme 4. Synthetic routes to 8-iodo- and 8-ethynyl-guanines from 2-amino-6-chloropurine.  
 
To circumvent these problems, substitution of the 6-chloro 
atom with a 2-trimethylsilylethoxy group[29] was next considered 
with the aim of reducing the reactivity of such position in the 
halogenation step. This particular protecting group was chosen 
because of several additional advantages in the synthetic route: 
it imparts solubility to the heterocyclic ring and can be efficiently 
deprotected in the presence of fluoride at the very last step in the 
route,[30] along with the TMSA group. Compound G7[30] was thus 
synthesized and subjected then to a halogenation reaction. 
Electrophilic iodination was first tested with negative results and 
 
 
 
 
 
 
the starting material was recovered in all cases. Bromination in 
the presence of Br2 did not work properly either. Contrarily, 
bromination with NBS led to G6, which could be subsequently 
alkylated. It is worth to note that the alkylation reaction on this 
substrate led to complete regioselectivity at N-9, both for alkyl and 
benzyl halides, affording G3Alk10 and G3Bn2. However, despite its 
convergence, we were still not very satisfied with this route since 
the first two reactions (nucleophilic aromatic substitution and 
bromination) proceeded with low to moderate yields, were not 
very reproducible, and the products obtained (G7 and G6) could 
not be easily isolated from traces of impurities. It is also important 
to note that G6 was unreactive in palladium-catalyzed couplings, 
either in Sonogashira reactions with TMSA or in Stille reactions in 
the presence of ethynyltributylstannane. Altering the sequence by 
alkylation of G7 led to more easily isolable products. The use of 
1-iododecane or 1-iodoethane in this reaction led now to a ca. 1:1 
mixture of N-7 and N-9 products, which is surprising in view of the 
higher regioselectivities attained in the alkylation reactions on G6 
or on 2-amino-6-chloropurine (see above). Bromination of G4Alk10 
or G4Alk2 led to the 8-bromopurines G3Alk10 or G3Alk2 in quite good 
yields.  
Nevertheless, the best route we found to our target lipophilic 
guanines is shown in the central region of Scheme 4. Alkylation 
was first performed on 2-amino-6-chloropurine using K2CO3 or 
Cs2CO3 as the base, as has been explained above. This reaction 
afforded rather soluble products with good yields that could be 
easily purified and subjected to the aromatic nucleophilic 
substitution with the 2-trimethylsilylethoxy group, leading to 
compounds G4Alk10, G4Alk2, and G4Bn3. As just mentioned, the 
G4Alk10 and G4Alk2 products could be brominated at the 8-position 
in the presence of NBS, but reaction of G4Bn3 in the presence of 
1 equivalent of NBS led instead to the selective bromination at the 
aromatic benzyl residue. Instead, iodination was essayed under a 
different mechanism that involved deprotonation at the guanine 8-
position in the presence of LDA and quenching of the resulting 
anion with iodine.[31] Product G2Bn3 was in this way generated with 
acceptable yields. This iodination procedure is, of course, also 
compatible with the alkylated purines. Finally, bromo-derivatives 
G3Alk10, G3Alk2 and G3Bn2, and iodoguanine G2Bn3 were subjected 
to a Sonogashira coupling in the usual conditions, followed by 
deprotection of the alkyne TMS group, to yield G1Alk10, G1Alk2, 
G1Bn2 and G1Bn3.  
The synthesis of 9-alkyl-8-ethynylguanines was as well 
attempted using guanine as a convenient starting material due 
principally to its low cost (Scheme 5). However, the extremely low 
solubility of this heterocyclic reagent has to be overcome first. The 
literature offers different methods to transiently transform guanine 
into products that display enough solubility to carry out several 
synthetic transformations.[32] Among the different methods we 
tested, we chose 2-amine protection as an isobutyryl amide due 
to the acceptable solubility and ease in isolation of the product. 
Compound G13 was thus synthesized in 80% yield in the 
presence of isobutyric anhydride.[33] This product could be 
halogenated in the presence of bromine and sodium acetate[34] 
leading to G12 in good yields. Direct attempts to perform a 
Sonogashira reaction with TMSA on compound G12 were 
unsuccessful in our hands, despite a related procedure was 
reported recently from similar substrates,[35] and the starting 
material was recovered instead. We thought that protection of the 
6-carbonyl group in G12 could increase its reactivity in palladium-
catalyzed couplings.[12] A diphenylcarbamoyl protecting group[36] 
was selected among diverse options, but compound G11 was still 
unreactive in any Pd-catalyzed Sonogashira or Stille reaction 
conditions we tried. Therefore, G11 was subjected first to an 
alkylation reaction either with ethyliodide, 3,4,5-
tris(dodecyloxy)benzyl bromide or with tertbutyl bromoacetate. 
Unexpectedly, in all cases this nucleophilic substitution reaction 
displayed very low regioselectivity, leading to a mixture of mono- 
and dialkylated products that complicated the purification process. 
G11 was alkylated at both the imidazole ring and at the amide 
protecting group. Not only that, despite the high steric hindrance 
of the diphenylcarbamoyl group, the N-7 substituted product 
turned out to be one of the major byproducts in this reaction. Only 
the target compound G10Es could be isolated in pure form in 28% 
yield from this mixture.  
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Scheme 5. Attempted synthetic route to 8-bromo- and 8-ethynyl-guanines from 
guanine. 
2-Aminoadenine (Scheme 6). Two alkylated adenine 
derivatives were prepared from commercial 2,6-diaminopurine. 
All our attempts to either iodinate or brominate this starting 
material were unsuccessful. Instead, the alkylation reaction[37] 
was carried out as the first step of the synthetic route. K2CO3 
proved to be the best base for such reaction due to handling 
conditions, price and yield reasons. Compounds A4Alk10 and 
A4Alk2 were prepared in this way. Next, the halogenation reaction 
was optimized. Iodination in the presence of periodic acid[38] was 
chosen over bromination reaction with NBS, not only due to the 
reasons stated above, but also because of the poor yields and 
reliability of the latter reaction, even with recrystallized NBS. It is 
worth to mention that none of the guanine derivatives tested could 
be iodinated under these conditions. Compounds A2Alk10, A2Alk2, 
and A3Alk10 were then subjected to the Sonogashira-TMS 
cleavage protocol, leading to A1Alk10 and A1Alk2 in good yields.  
 
 
 
 
 
 
 
Scheme 6. Optimized synthetic route to 8-iodo- and 8-ethynyl-diaminopurine and 8-ethynyl-isoguanine. 
Isoguanine (Scheme 6). The isoguanine non-natural 
nucleobase could be obtained from 2,6-diaminopurine in a single 
step by selective hydrolysis at C-2 via a diazonium intermediate. 
[39] For the sake of simplicity and convergence, we performed this 
process after the cross-coupling reaction of the iodinated A2 
derivatives and before TMS deprotection, since the terminal 
ethynyl group was found to interfere in this reaction. Compound 
iG1Alk2 was isolated in 73% overall yield from A2Alk2 after TMS-
cleavage in the presence of K2CO3.  
Conclusions 
In this work we have prepared a series of lipophilic nucleobases, 
comprising natural and non-natural derivatives, that are 
substituted at the 5- (pyrimidines) or 8-position (purines) with 
either a halogen atom or a terminal triple bond. These include 
cytosine, isocytosine and uracil as pyrimidine heterocycles, and 
guanine, isoguanine, and 2-aminoadenine as complementary 
purine bases. The N-1 / N-9 position of these compounds was 
functionalized with alkyl or benzyl groups, as well as with amine 
or carboxylic acid precursors. This kind of functional groups are 
suited to afford solubility and direct nucleobase assembly in 
organic solvents or onto surfaces, as we are studying in our group 
at the moment. The synthetic sequences leading to the final 
ethynylated compounds have been optimized for each base 
attending to convergence, convenience, ease of purification and 
overall yields. Our results indicate that the choice of reaction 
conditions and the order in which the halogenation, alkylation and 
Sonogashira steps are performed is not always trivial and each 
base requires a particular optimized protocol.  
The molecules prepared in this work can be regarded as a 
relevant collection of “supramolecular synthons” to which a wide 
diversity of functional units may be attached by means of metal-
catalyzed cross-coupling or “click” reactions, in order to guide 
their organization.   
Experimental Section 
General Information.  
Chemicals were purchased from commercial suppliers and used without 
further purification. Solid, hygroscopic reagents were dried in a vacuum 
oven before use. N-Bromosuccinimide (NBS) was recrystallized twice from 
water. Reaction solvents were thoroughly dried before use using standard 
methods. Column chromatography was carried out on silica gel Merck-60 
(230-400 mesh, 60 Å), and TLC on aluminium sheets precoated with silica 
gel 60 F254 (Merck). LSI-MS and HR-MS spectra were determined on a 
VG AutoSpec apparatus (FAB) or an Applied Biosystems QSTAR 
equipment (ESI) in the positive mode. MALDI-TOF-MS spectra were 
obtained from a BRUKER ULTRAFLEX III instrument equipped with a 
nitrogen laser operating at 337 nm. NMR spectra were recorded with a 
BRUKER AC-300 (300 MHz) instrument. The temperature was actively 
controlled at 298 K. Chemical shifts are measured in ppm using the signals 
of the deuterated solvent as the internal standard [CHCl3, calibrated at 
7.26 ppm (1H) and 77.0 ppm (13C); DMSO calibrated at 2.50 ppm (1H) and 
39.5 ppm (13C)].  
Compounds G8Alk10, G9Alk10 and G3Bn2 were not isolated. The synthesis 
and characterization of compounds 5-iodocytosine C3,[40] 5-iodo-
isocytosine iC3,[19] guanine G13,[33] 3,5-bis(dodecyloxy)benzyl chloride,[41] 
and 3,4,5-tris(dodecyloxy)benzyl bromide[42] has been reported elsewhere.  
Synthesis of the cytosine derivatives.  
5-iodocytosine (C3): C3 was synthesized according to a literature 
procedure[13] adapted to our molecule. Cytosine (10.0 g, 90.0 mmol), 
iodine (34.3 g, 135.0 mmol) and iodic acid (22.2 g, 126.0 mmol) were 
stirred in acetic acid (300 mL) at 40 °C overnight. Once completed, the 
reaction mixture was cooled and treated with Na2S2O3 (sat) (200 mL) until 
a white suspension was obtained. The mixture was then neutralized with 
NaOH 6M (900 mL). The resulting white solid was filtered and washed with 
slightly basified water until the filtered water had neutral pH. C3 was dried 
under reduced pressure affording 20.6 g (96% yield). 1H NMR (300 MHz, 
DMSO-d6): δ = 10.76 (bs, 2H, N1H), 7.76 (s, 1H, H6), 6.48 (bs, 2H, NH2) 
ppm. 13C NMR (75 MHz, CDCl3): δ = 164.4, 155.8, 149.4, 55.2 ppm. HRMS 
 
 
 
 
 
 
(ESI+): Calculated for C4H5N3OI: 237.9471 [M+H]+. Found: 237.9464 
[M+H]+. 
Standard Procedure A for the Nucleobase alkylation reaction. To a 
suspension of the nucleobase starting material (1 eq) and a base (1.2 eq) 
(indicated in each case) in dry DMF (volume indicated in each case) was 
added dropwise the corresponding iodoalkane or benzyl bromide/chloride 
(1.2 eq) (indicated in each case). The mixture was stirred under argon at 
40 ⁰C for a period of time (indicated in each case) until completion, which 
was monitored by TLC. Work-up and purification methods are indicated in 
each case. 
1-decyl-5-iodocytosine (C2Alk10): C2Alk10 was synthesized according to a 
literature procedure[14] adapted to our molecule. C2Alk10 can be obtained 
following Standard Procedure A using C3 (10.0 g, 42.2 mmol), a 1.0 M 
solution in MeOH of Bu4NOH (50.6 mL, 50.6 mmol), 1-iododecane (11.0 
mL, 50.6 mmol) and DMF (150 mL). The reaction was completed in 12 h. 
Then, the reaction mixture was poured into 150 mL of water and the 
precipitated solid was filtered, washed with water and dried. The resulting 
solid was washed with acetonitrile affording 9.8 g of C2Alk10 (62% yield). 
C2Alk10 can also be obtained by stirring C4Alk10 (15.7 g, 62.5 mmol), iodine 
(10.1 g, 40.5 mmol) and iodic acid (13.2 g, 76.0 mmol) in 400 mL acetic 
acid at 40 °C overnight. Once completed, the reaction mixture was cooled 
and the unsoluble iodic acid was filtered away. The resulting mixture was 
extracted with ethylacetate and washed with water (3 x 400 mL), NaHCO3 
(sat) (3 x 400 mL), Na2S2O3 (sat) (400 mL) and brine (400 mL). The organic 
layer was dried over MgSO4 and concentrated in vacuo. The resulting solid 
was washed with ether affording C2Alk10 as a bright beige solid; m. p. 163-
165 ºC (15.8 g, 81%). 1H NMR (300 MHz, DMSO-d6): δ = 8.07 (s, 1H, H6), 
7.58 (bs, 1H, NH2), 6.43 (bs, 1H, NH2), 3.7-3.6 (m, 2H, N1CH2C9H19), 1.6-
1.4 (m, 2H, N1CH2CH2C8H17), 1.4-1.1 (m, 14H, N1C2H4C7H14CH3), 0.85 (t, 
J = 7.0 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ = 164.8, 155.4, 
150.9, 55.0, 50.5, 31.8, 29.5, 29.4, 29.3, 29.23, 29.17, 26.5, 22.6, 14.1 
ppm. HRMS (ESI+): Calculated for C14H25N3OI: 378.1036 [M+H]+. Found: 
378.1028 [M+H]+. 
1-hexyl-5-iodocytosine (C2Alk6): C2Alk6 can be obtained following 
Standard Procedure A using C3 (5.0 g, 21.1 mmol), a 1.0 M solution in 
MeOH of Bu4NOH (25 mL, 25.3 mmol), 1-iodohexane (4 mL, 25.3 mmol) 
and DMF (75 mL). The reaction was completed in 8 h. The reaction mixture 
was then poured into 75 mL of water and the precipitated solid was filtered, 
washed with water and dried. The resulting solid was purified by column 
chromatography on silica gel eluted with CHCl3/MeOH; (50:1), affording 
4.0 g of C2Alk6 (59% yield) as a pale solid; m. p. 165-166 ºC. 1H NMR (300 
MHz, CDCl3): δ = 8.39 (bs, 1H, NH2), 7.54 (s, 1H, H6), 5.54 (bs, 1H, NH2), 
3.73 (m, 2H, N1CH2C5H11), 1.8-1.6 (m, 2H, N1CH2CH2C4H9), 1.4-1.2 (m, 
6H, N1C2H4C3H6CH3), 0.87 (t, J = 6.6 Hz, 3H, CH3) ppm. 13C NMR (75 
MHz, DMSO-d6): δ = 163.9, 154.6, 151.9, 55.0, 48.6, 30.8, 28.6, 25.5, 21.9, 
13.8 ppm. HRMS (ESI+): Calculated for C10H17N3OI: 322.0410 [M+H]+. 
Found: 322.0405 [M+H]+. 
1-ethyl-5-iodocytosine (C2Alk2): C2Alk2 can be obtained following 
Standard Procedure A using C3 (10.0 g, 42.2 mmol), a 1.0 M solution in 
MeOH of Bu4NOH (50.6 mL, 50.6 mmol), 1-iododecane (11 mL, 50.6 
mmol) and DMF (150 mL). The reaction was completed in 5 h. After solvent 
evaporation, the crude solid was purified by column chromatography on 
silica gel eluted with CHCl3/MeOH; (20:1). A final recrystallization using 
acetonitrile yielded C2Alk2 as a white solid (2.2 g, 40%). C2Alk2 can also be 
obtained by stirring C4Alk2 (1.0 g, 7.2 mmol), iodine (2.8 g, 11.1 mmol) and 
iodic acid (1.5 g, 8.8 mmol) in 20 mL acetic acid at 40 °C. The reaction was 
completed in 4h. Then, the reaction mixture was cooled to room 
temperature and the unsoluble iodic acid was filtered away. The mixture 
was extracted with CHCl3 and washed with water (3 x 10 mL), NaHCO3 
(sat) (3 x 10 mL), Na2S2O3 (sat) (10 mL) and brine (10 mL). The organic 
layer was dried over MgSO4 and concentrated in vacuo. The resulting solid 
was purified by column chromatography on silica gel eluted with 
CHCl3/MeOH; (20:1), affording C2Alk2 as a white solid; m. p. 203-204 ºC 
(0.7 g, 36%). 1H NMR (300 MHz, DMSO-d6): δ = 8.09 (s, 1H, H6), 7.61 (bs, 
1H, NH2), 6.46 (bs, 1H, NH2), 3.67 (q, J = 7.0 Hz, 2H, N1CH2CH3), 1.13 (t, 
J = 7.0 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 163.9, 154.4, 
151.6, 55.2, 43.8, 14.5 ppm. HRMS (ESI+): Calculated for C6H9N3OI: 
265.9784 [M+H]+. Found: 265.9781 [M+H]+. 
1-(3,5-bis(dodecyloxy)benzyl)-5-iodocytosine (C2Bn2): Following 
Standard Procedure A for the alkylation reaction, to a suspension of C3 
(500 mg, 2.26 mmol) in dry DMF (25 mL), a 1.0 M solution of Bu4NOH in 
MeOH (2.26 mL, 2.26 mmol) was added. The resulting mixture was stirred 
at 40 ºC for 1 h. Then 1-(chloromethyl)-3,5-bis(dodecyloxy)benzene (1.34 
g, 2.72 mmol) was added and the resulting solution was stirred at 40 ºC 
for 16 h. Once the reaction was completed, the solvent was evaporated 
under reduced pressure. The crude was dissolved in CH2Cl2 (10 mL), 
washed with water (3 x 10 mL) and brine (10 mL). The combined organic 
layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purificated by column cromatography eluted with CHCl3/MeOH (50:1). 
C2Bn2 was obtained as a white solid; m. p. 125-127 ºC (234 mg, 40%). 1H 
NMR (300 MHz, CDCl3): δ = 7.51 (s, 1H, H6), 6.42 (d, J = 2.1 Hz, 3H, Ar-
2,4,6), 4.89 (s, 2H, N1CH2), 3.91 (t, J = 6.5 Hz, 4H, OCH2), 1.75 (p, J = 6.8 
Hz, 6H, OCH2CH2), 1.61-1.06 (m, 36H, OCH2CH2(CH2)9CH3), 1.06-0.78 
(m, 6H, O(CH2)11CH3). 13C NMR (75 MHz, CDCl3): δ = 163.7, 161.0, 155.7, 
150.6, 137.9, 106.9, 101.2, 77.2, 68.4, 55.8, 52.6, 32.1, 29.8, 29.8, 29.8, 
29.7, 29.6, 29.5, 29.4, 26.2, 22.8, 14.3 ppm. HRMS (ESI+): Calculated for 
C35H59N3O3I: 696.3595 [M+H]+. Found: 696.3581 [M+H]+. 
1-(3,4,5-tris(dodecyloxy)benzyl)-5-iodocytosine (C2Bn3): Following 
Standard Procedure A, to a solution of C3 (1.0 g, 4.22 mmol) in dry DMF 
(100 mL), a 1.0 M solution of Bu4NOH in MeOH was added (4.22 mL, 4.22 
mmol) and the mixture was stirred for 30 minutes at 50 ºC. Then, 1-
(bromomethyl)-3,4,5-tris(dodecyloxy)benzene (3.36 g, 4.64 mmol) was 
dissolved in dry DMF (50 mL) and added via cannula to the solution. This 
solution was stirred for 12 h. After completion, the solvent was evaporated 
under reduced pressure. The residue was purified by column 
chromatography eluted with CHCl3/MeOH (20:1) to afford C2Bn3 as a white 
solid; m. p. 115-117 ºC (2.8 g, 76%). 1H NMR (300 MHz, CDCl3): δ = 9.10 
(bs, 1H, C4NH-H), 7.48 (s, 1H, H6), 6.46 (s, 2H, Ar-2,4,6), 5.65 (s, 1H, 
C4NH-H), 4.82 (s, 2H, N1CH2), 3.92 (t, J = 6.3 Hz, 6H, OCH2), 1.75 (m, 6H, 
OCH2CH2), 1.24 (m, 34H, OCH2CH2(CH2)9CH3), 0.86 (m, 9H, 
O(CH2)11CH3). 13C NMR (75 MHz, CDCl3) δ = 165.0, 155.1, 153.6, 148.3, 
138.4, 130.6, 107.1, 90.2, 84.0, 77.3, 75.0, 73.4, 69.3, 52.7, 32.0, 30.4, 
29.8, 29.7, 29.5, 26.17, 22.74, 14.2 ppm. HRMS (ESI+) Calculated for 
C47H82IN3O4: 880.5422 [M+H]+. Found: 880.5454 [M+H]+. 
1-(2-(tert-butylcarbamate)ethyl)-5-iodocytosine (C2Am): A suspension 
of C3 (3.0 g, 12.65 mmol) and Cs2CO3 (4.9 g, 15.19 mmol) in dry DMF (75 
mL) was stirred at room temperature for 1.5 h. Then 2-(Boc-
amino)ethylbromide (3.4 g, 15.19 mmol) diluted in dry DMF (5 mL) was 
added via cannula and the resulting suspension was stirred at room 
temperature for 12 h. Once the reaction was completed, the resulting solid 
was filtered, washed with water and dried under vacuum to afford C2Am as 
a white solid; m. p. 231-233 ⁰C (3.92 g, 82%). 1H NMR (300 MHz, CDCl3): 
δ = 7.80 (s, 1H, H6), 7.60 (s, 1H, C4NH-H), 6.85 (bs, 1H, N1CH2CH2-NH), 
 
 
 
 
 
 
6.43 (bs, 1H, C4NH-H), 3.66 (d, J = 5.8 Hz, 2H, N1CH2CH2), 3.14 (d, J = 
5.8 Hz, 2H, N1CH2CH2), 1.35 (s, 9H, OC(CH3)3). 13C NMR (75 MHz, 
DMSO-d6): δ = 164.0, 155.6, 154.6, 152.1, 55.0, 48.7, 39.5, 38.5, 28.2 ppm. 
HRMS (ESI+) Calculated for C11H18IN4O3: 381.0418 [M+H]+. Found: 
381.0403 [M+H]+. 
Standard Procedure B for the Sonogashira coupling[41] with TMSA 
and subsequent alkyne-TMS group deprotection. A dry THF/NEt3 (4:1) 
solvent mixture was subjected to deoxygenation by three freeze-pump-
thaw cycles with argon. Then, this solvent was added over the system 
containing the corresponding halogenated base (1 eq), Cul (0.01 eq) and 
Pd(PPh3)2Cl2 (0.02 eq). The mixture was stirred at room temperature 
during a few minutes. Then, trimethylsilylacetylene (TMSA; 2 eq) was 
added dropwise. The reaction was stirred under argon at a given 
temperature for a period of time (indicated in each case) until completion, 
which was monitored by TLC. Then, the mixture was filtrated over celite 
and the solvent evaporated under vacuum. The resulting crude was placed 
in a round-bottomed flask equipped with a magnetic stirrer, THF was 
added and the mixture was stirred at room temperature until the solid was 
dissolved. Then, hydrated tetrabutylammonium fluoride (TBAF·3H2O; 1 
eq) was slowly added at 0 ºC, and the mixture was stirred at room 
temperature until reaction completion, which was monitored by TLC 
(approximately 1 hour in all cases). The solvent was evaporated at 
reduced pressure and the product was purified by column chromatography 
(eluent indicated in each case). The resulting solid was finally washed with 
cold acetonitrile. 
1-decyl-5-ethynyl-cytosine (C1Alk10): C1Alk10 was prepared following 
Standard Procedure B. C2Alk10 (10.0 g, 26.5 mmol), Pd(PPh3)2Cl2 (372.1 
mg, 0.53 mmol) and CuI (50.4 mg, 0.27 mmol) were dissolved in the 
THF/NEt3 mixture (125 mL). Then TMSA (9.8 mL, 53.0 mmol) was added. 
The reaction was completed in 12 h. Then, TBAF·3H2O (9.2 g, 29.2 mmol) 
was added over a THF (130 mL) solution of the crude mixture. C1Alk10 was 
purified by column chromatography on silica gel eluted with CHCl3/AcOEt 
(20:1). A final recrystallization using acetonitrile yielded C1Alk10 as a brown 
solid; m. p. 139-141 ºC (4.7 g, 65%). 1H NMR (300 MHz, DMSO-d6): δ = 
8.05 (s, 1H, H6), 7.50 (bs, 1H, NH2), 6.66 (bs, 1H, NH2), 4.30 (s, 1H, C≡CH), 
3.7-3.6 (m, 2H, N1CH2C9H19), 1.6-1.4 (m, 2H, N1CH2CH2C8H17), 1.3-1.1 (m, 
14H, N1C2H4C7H14CH3), 0.85 (t, J = 6.6 Hz, 3H, CH3) ppm. 13C NMR (75 
MHz, DMSO-d6): δ = 164.9, 154.8, 148.8, 89.5, 83.7, 74.9, 50.6, 31.8, 29.4, 
29.3, 29.2, 29.12, 29.10, 26.4, 22.6, 14.0 ppm. HRMS (ESI+): Calculated 
for C16H26N3O: 276.2070 [M+H]+. Found: 276.2079 [M+H]+. 
1-hexyl-5-ethynyl-cytosine (C1Alk6): C1Alk6 was prepared following 
Standard Procedure B. C2Alk6 (3.7 g, 11.6 mmol), Pd(PPh3)2Cl2 (162 mg, 
0.23 mmol) and CuI (22 mg, 0.12 mmol) were dissolved in the THF/NEt3 
mixture (70 mL). Then TMSA (3.3 mL, 23.1 mmol) was added. The 
reaction was completed in 12 h. Then, TBAF·3H2O (3.7 g, 11.6 mmol) was 
added over a THF (60 mL) solution of the crude mixture. C1Alk6 was 
purified by column chromatography on silica gel eluted with CHCl3/MeOH; 
(50:1). A final recrystallization using acetonitrile yielded C1Alk6 as an ochre 
solid; m. p. 163-164 ºC (2.1 g, 81%). 1H NMR (300 MHz, CDCl3): δ = 7.54 
(s, 1H, H6), 6.89 (bs, 1H, NH2), 5.64 (bs, 1H, NH2), 3.77 (m, 2H, 
N1CH2C5H11), 3.35 (s, 1H, C≡CH), 1.8-1.6 (m, 2H, N1CH2CH2C4H9), 1.4-
1.2 (m, 6H, N1C2H4C3H6CH3), 0.88 (t, J = 6.6 Hz, 3H, CH3) ppm. 13C NMR 
(75 MHz, CDCl3): δ = 164.7, 154.8, 149.1, 89.2, 83.7, 75.0, 50.7, 31.4, 
29.2, 26.2, 22.5, 14.0 ppm. HRMS (FAB+): Calculated for C12H18N3O: 
220.1450 [M+H]+. Found: 220.1445 [M+H]+. 
1-ethyl-5-ethynyl-cytosine (C1Alk2): C1Alk2 was prepared following 
Standard Procedure B. C2Alk2 (1.5 g, 5.7 mmol), Pd(PPh3)2Cl2 (79.5 mg, 
0.11 mmol) and CuI (10.8 mg, 0.06 mmol) were dissolved in the THF/NEt3 
mixture (15 mL). Then TMSA (2 mL, 11.3 mmol) was added. The reaction 
was completed in 12 h. Then, TBAF·3H2O (1.8 g, 5.7 mmol) was added 
over a THF (50 mL) solution of the crude mixture. C1Alk2 was purified by 
column chromatography on silica gel eluted with CHCl3/AcOEt; (20:1). A 
final recrystallization using acetonitrile yielded C1Alk2 as a white solid; m. 
p. 196-197 ºC (0.51 g, 55%). 1H NMR (300 MHz, CDCl3): δ = 7.79 (bs, 1H, 
NH2), 7.55 (s, 1H, H6), 5.76 (bs, 1H, NH2), 3.84 (q, J = 7.2 Hz, 2H, 
N1CH2CH3), 3.35 (s, 1H, C≡CH), 1.32 (t, J = 7.2 Hz, 3H, CH3) ppm. 13C 
NMR (75 MHz, CDCl3): δ = 164.7, 154.6, 148.6, 89.7, 83.8, 74.9, 45.6, 
14.6 ppm. HRMS (ESI+): Calculated for C8H10N3O: 164.0818 [M+H]+. 
Found: 164.0822 [M+H]+. 
1-(3,5-bis(dodecyloxy)benzyl) 5-ethynylcytosine (C1Bn2): Following 
Standard Procedure B, C2Bn2 (1.1 g, 1.58 mmol), CuI (0.03 mg, 0.0158 
mmol) and Pd(Ph3)2Cl2 (22 mg, 0.032 mmol) were dissolved in the 
THF/NEt3 mixture (15 mL). Then, TMSA (0.6 mL, 4.74 mmol) was added 
and the mixture was stirred at 40 ºC overnight. Once the reaction was 
completed, the solvent was evaporated under reduced pressure. The 
residue was dissolved in THF (15 mL) and TBAF·3H2O (553 mg, 1.58 
mmol) was added. Once the deprotection was completed, the solvent was 
removed under reduced pressure. The crude was purified by column 
chromatography eluted with CHCl3/MeOH (100:1) and recrystallized from 
CHCl3/MeCN. A light brown solid was obtained; m. p. 103-105 ºC (902 mg, 
82%). 1H NMR (300 MHz, CDCl3): δ = 8.41 (bs, 1H, C4NH-H), 7.51 (s, 1H, 
H6C), 6.40 (s, 3H, Ar-2,4,6), 6.20 (s, 1H, C4NH-H), 4.89 (s, 2H, N1CH2), 
3.91 (t, J = 6.5 Hz, 4H, OCH2), 3.36 (s, 1H, C≡CH), 1.74 (dt, J = 8.3, 6.5 
Hz, 6H, OCH2CH2), 1.62-1.11 (m, 36H, OCH2CH2(CH2)9CH3), 1.00-0.75 
(m, 6H, O(CH2)11CH3). 13C NMR (75 MHz, CDCl3): δ = 163.8, 161.1, 148.9, 
137.1, 107.1, 101.3, 84.9, 77.3, 74.1, 68.4, 52.8, 32.1, 29.8, 29.7, 29.6, 
29.5, 29.4, 26.2, 22.84, 14.3 ppm. HRMS (ESI+): Calculated for 
C37H60N3O3: 594.4629 [M+H]+. Found: 594.4667 [M+H]+. 
1-(3,4,5-tris(dodecyloxy)benzyl)-5-ethynylcytosine (C1Bn3): Following 
Standard Procedure B, to a solution of C2Bn3 (500 mg, 0.568 mmol), 
Pd(Ph3)2)Cl2 (7.71 mg, 0.011 mmol), and CuI (1.07 mg, 0.006 mmol) in 
THF/NEt3 (5 mL), TMSA (1.4 mL, 2.27 mmol) was added and the mixture 
stirred at 40ºC overnight. Once the reaction was completed, the solvent 
was evaporated, the resulting crude was suspended in THF (10 mL) and 
TBAF·3H2O (625 mg, 0.625 mmol) was added. After completion the 
solvent was evaporated and the resulting residue was purified by column 
chromatography eluted with CHCl3/MeOH (50:1), affording C1Bn3 (340 mg, 
77%) as a pale solid; m. p. 94-96 ºC. 1H NMR (300 MHz, CDCl3): δ = 7.47 
(s, 1H, H6), 6.87 (bs, 1H, C4NH-H), 6.49 (s, 2H, Ar-2,6), 5.67 (bs, 1H, 
C4NH-H), 4.87 (s, 2H, N1CH2), 3.93 (td, J = 6.5, 2.2 Hz, 6H, OCH2), 3.32 
(s, 1H, C≡CH), 1.89-1.52 (m, 8H, OCH2CH2), 1.28 (m, 64H, 
OCH2CH2(CH2)9CH3), 1.03-0.67 (m, 9H, O(CH2)11CH3). 13C NMR (75 MHz, 
CDCl3): δ = 165.0, 155.1, 153.6, 148.3, 138.4, 130.6, 107.1, 90.2, 84.0, 
77.3, 75.0, 73.4, 69.3, 52.7, 32.0, 30.4, 29.8, 29.7, 29.5, 26.2, 22.7, 14.2 
ppm. HRMS (ESI+) Calculated for C49H84N3O4: 778.6456 [M+H]+. Found: 
778.6464 [M+H]+. 
1-(2-(tert-butylcarbamate)ethyl)-5-ethynylcytosine (C1Am): Following 
Standard Procedure B, C2Am (3.0 g, 7.9 mmol), Pd(PPh3)2Cl2 (140 mg, 0.2 
mmol) and CuI (20 mg, 0.1 mmol) were dissolved in the THF/NEt3 mixture. 
TMSA (3.4 mL, 23.9 mmol) was added and the mixture heated at 40 ºC for 
12 h. After completion, the solvent was evaporated. The resulting crude 
and TBAF·3H2O (2.7 g, 8.9 mmol) were dissolved in a 1:1 CH2Cl2/THF 
 
 
 
 
 
 
mixture and stirred at room temperature for 1 h until the reaction was 
completed. The solvent was then evaporated under reduced pressure. The 
resulting solid was purified by column chromatography eluted with 
CHCl3/MeOH (20:1) to afford C1Am as a light brown solid; m. p. 205-206 
⁰C (1.57 g, 71%). 1H NMR (300 MHz, DMSO-d6): δ = 7.77 (s, 1H, H6), 7.51 
(bs, 1H, C4NH-H), 6.85 (bs, 1H, N1CH2CH2-NH), 6.64 (bs, 1H, C4NH-H), 
4.30 (s, 1H, C≡CH), 3.69 (m, 2H, N1CH2CH2), 3.16 (m, 3H, N1CH2CH2), 
1.34 (s, 9H, OC(CH3)3) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 164.6, 
155.6, 154.0, 150.5, 87.7, 85.6, 77.8, 75.9, 49.1, 28.1, 1.9 ppm. HRMS 
(FAB+): Calculated for C13H18N4O3: 279.1457 [M+H]+. Found: 279.1457 
[M+H]+. 
1-decyl-cytosine (C4Alk10): C4Alk10 was synthesized according to a 
literature procedure[14] adapted to our molecule. C4Alk10 was obtained 
following Standard Procedure A using cytosine (10.0 g, 90 mmol), a 1.0 M 
solution in MeOH of Bu4NOH (108 mL, 108 mmol), 1-iododecane (19 mL, 
108 mmol) and DMF (500 mL). The reaction was completed in 12 h. Then, 
the reaction mixture was poured into 150 mL of water and the precipitated 
solid was filtered, washed with water and dried. The resulting solid was 
washed with acetonitrile affording 15.8 g (70% yield) of a pale solid. 1H 
NMR (300 MHz, DMSO-d6): δ = 7.54 (d, J = 7.0 Hz, 1H, H6), 6.91 (bs, 2H, 
NH2), 5.61 (d, J = 7.0 Hz, 1H, H5), 3.59 (m, 2H, N1CH2C9H19), 1.53 (m, 2H, 
N1CH2CH2C8H17), 1.3-1.1 (m, 14H, N1C2H4C7H14CH3), 0.85 (t, 3H, CH3) 
ppm. 13C NMR (75 MHz, DMSO-d6): δ = 165.8, 155.8, 146.0, 93.0, 48.6, 
38.5, 31.2, 28.9, 28.6, 25.9, 22.0, 13.9 ppm. HRMS (ESI+): Calculated for 
C14H26N3O: 252.2070 [M+H]+. Found: 252.2082 [M+H]+. 
1-ethyl-cytosine (C4Alk2): C4Alk2 was obtained following Standard 
Procedure A using cytosine (5.0 g, 45 mmol), a 1.0 M solution in MeOH of 
Bu4NOH (54 mL, 54 mmol), 1-iodoethane (4.5 mL, 54 mmol) and DMF 
(150 mL). The reaction was completed in 12 h. After solvent evaporation, 
the crude solid was purified by column chromatography on silica gel eluted 
with CHCl3/MeOH (20:1). A final recrystallization using acetonitrile yielded 
C4Alk2 as a white solid (1.2 g, 19%). 1H NMR (300 MHz, DMSO-d6): δ = 
7.59 (d, J = 7.0 Hz, 1H, H6), 7.02 (bs, 2H, NH2), 5.64 (d, J = 7.0 Hz, 1H, 
H5), 3.65 (q, J = 7.0 Hz, 2H, N1CH2CH3), 1.13 (t, J = 7.0 Hz, 3H, CH3) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 165.5, 155.2, 145.9, 93.3, 43.7, 14.5 
ppm. HRMS (ESI+): Calculated for C6H10N3O: 140.0818 [M+H]+. Found: 
140.0813 [M+H]+. 
Synthesis of the uracil derivatives.  
1-decyl-5-iodouracil (U2Alk10): U2Alk10 was obtained following Standard 
Procedure A using 5-iodouracil (5.0 g, 21 mmol), Cs2CO3 (8.2 g, 25.2 
mmol), 1-iododecane (5.4 mL, 25.2 mmol) and DMF (100 mL). The 
reaction was completed in 4 h. After solvent evaporation, the crude was 
dissolved in CHCl3 (200 mL) and washed with water (3 x 100 mL) and brine 
(100 mL). The organic layer was dried over MgSO4 and concentrated in 
vacuo. The crude solid was purified by column chromatography on silica 
gel eluted with CHCl3/MeOH (200:1). U2Alk10 was obtained as a white solid; 
m. p. 148-149 ºC (3.6 g, 45%). 1H NMR (300 MHz, DMSO-d6): δ = 11.58 
(bs, 1H, N3H), 8.20 (s, 1H, H6), 3.64 (t, J = 6.9 Hz, 2H, N1CH2C9H19), 1.55 
(m, 2H, N1CH2CH2C8H17), 1.3-1.1 (m, 14H, N1C2H4C7H14CH3), 0.85 (t, J = 
6.9 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 160.8, 150.7, 
150.0, 67.5, 49.1, 31.7, 29.3, 29.2, 29.1, 29.00, 28.96, 26.2, 22.5, 13.5 
ppm. HRMS (FAB+): Calculated for C14H24N2O2I: 379.0883 [M+H]+. 
Found: 379.0881 [M+H]+. 
1-hexyl-5-iodouracil (U2Alk6): U2Alk6 was obtained following Standard 
Procedure A using 5-iodouracil (3.0 g, 12.6 mmol), Cs2CO3 (4.9 g, 15.1 
mmol), 1-iodohexane (2.2 mL, 15.1 mmol) and DMF (200 mL). The 
reaction was completed in 4 h. After solvent evaporation, the crude solid 
was purified by column chromatography on silica gel eluted with 
CHCl3/MeOH (200:1). U2Alk6 was obtained as a white solid (0.64 g, 16%).  
1H NMR (300 MHz, CDCl3): δ = 8.20 (bs, 1H, N3H), 7.60 (s, 1H, H6), 3.73 
(t, J = 7.4 Hz, 2H, N1CH2C5H11), 1.7-1.6 (m, 2H, N1CH2CH2C4H9), 1.3-1.2 
(m, 6H, N1C2H4C3H6CH3), 0.90 (t, J = 7.0 Hz, 3H, CH3) ppm. 13C NMR (75 
MHz, CDCl3): δ = 169.5, 154.3, 148.9, 67.3, 49.2, 31.2, 29.1, 26.0, 22.4, 
13.9 ppm. HRMS (ESI+): Calculated for C10H16N2O2I: 323.0251 [M+H]+. 
Found: 323.0249 [M+H]+. 
1-decyl-5-ethynyl-uracil (U1Alk10): U1Alk10 was prepared following 
Standard Procedure B. U2Alk10 (3.2 g, 8.4 mmol), Pd(PPh3)2Cl2 (117.6 mg, 
0.17 mmol) and CuI (15.9 mg, 0.08 mmol) were dissolved in the THF/NEt3 
mixture (60 mL). Then TMSA (3.1 mL, 16.8 mmol) was added. The 
reaction was completed in 12 h. Then, TBAF·3H2O (2.7 g, 8.4 mmol) was 
added over a THF (60 mL) solution of the crude mixture. U1Alk10 was 
purified by column chromatography on silica gel eluted with 
hexane/AcOEt; (4:1) affording U1Alk10 as a white solid (461 mg, 65%). 1H 
NMR (300 MHz, CDCl3): δ = 8.16 (bs, 1H, N3H), 7.49 (s, 1H, H6), 3.74 (t, 
J = 6.7 Hz, 2H, N1CH2C9H19), 3.21 (s, 1H, C≡CH), 1.8-1.6 (m, 2H, 
N1CH2CH2C8H17), 1.3-1.2 (m, 14H, N1C2H4C7H14CH3), 0.88 (t, J = 6.7 Hz, 
3H, CH3) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 161.6, 149.5, 148.0, 
98.7, 82.1, 74.4, 49.4, 31.8, 29.7, 29.44, 29.37, 29.2, 29.1, 26.3, 22.6, 14.1 
ppm. HRMS (ESI+): Calculated for C16H25N2O2: 277.1910 [M+H]+. Found: 
277.1910 [M+H]+. Calculated for C16H24N2O2Na: 299.1729 [M+H]+. Found: 
299.1750 [M+H]+. 
1-hexyl-5-ethynyl-uracil (U1Alk6): U1Alk6 was prepared following Standard 
Procedure B. U2Alk6 (0.64 g, 2.0 mmol), Pd(PPh3)2Cl2 (27.9 mg, 0.04 
mmol) and CuI (3.8 mg, 0.02 mmol) were dissolved in the THF/NEt3 
mixture (20 mL). Then TMSA (0.6 mL, 4.0 mmol) was added. The reaction 
was completed in 8 h. Then, TBAF·3H2O (0.6 g, 2.0 mmol) was added over 
a THF (15 mL) solution of the crude mixture. U1Alk6 was purified by column 
chromatography on silica gel eluted with CHCl3/hexane; (100:1) affording 
U1Alk6 as a white solid; m. p. 149-151 ºC (216 mg, 49%). 1H NMR (300 
MHz, CDCl3): δ = 8.31 (bs, 1H, N3H), 7.49 (s, 1H, H6), 3.74 (t, J = 7.0 Hz, 
2H, N1CH2C5H11), 3.21 (s, 1H, C≡CH), 1.8-1.6 (m, 2H, N1CH2CH2C4H9), 
1.4-1.2 (m, 6H, N1C2H4C3H6CH3), 0.89 (t, J = 6.7 Hz, 3H, CH3) ppm. 13C 
NMR (75 MHz, DMSO-d6): δ = 161.9, 149.8, 148.1, 98.7, 82.1, 74.5, 49.4, 
31.2, 29.0, 26.0, 22.4, 13.9 ppm. HRMS (ESI+): Calculated for 
C12H17N2O2: 221.1284 [M+H]+. Found: 221.1281 [M+H]+. 
Synthesis of the isocytosine derivatives. 
5-iodoisocytosine (iC3):[19] Isocytosine (1.0 g, 9.0 mmol) was suspended 
in a 1:1 AcOH/H2O mixture (35 mL). The reaction mixture was stirred at 50 
ºC for 15 minutes. Then N-iodosuccinimide (2.4 g, 10.8 mmol) was added 
and the mixture was stirred at 100 ºC for 2 hours. Once completed, the 
reaction mixture was cooled to room temperature and the resulting cream-
colored solid was filtered and washed with water, affording 1.7 g of iC3 
(81% yield). 1H NMR (300 MHz, DMSO-d6): δ = 11.26 (bs, 1H, N3H). 7.93 
(s, 1H, H6); 6.71 (bs, 2H, NH2). 13C NMR (75 MHz, DMSO-d6): δ = 161.5, 
159.6, 156.6, 71.0 ppm. HRMS (ESI+): Calculated for C4H5N3OI: 237.9471 
[M+H]+. Found: 237.9464 [M+H]+. 
1-ethyl-5-iodoisocytosine (iC2Alk2): iC2Alk2 was obtained following 
Standard Procedure A using iC3 (1.7 g, 7.3 mmol), a 1.0 M solution in 
MeOH of Bu4NOH (8.8 mL, 8.8 mmol), 1-iodoethane (0.72 mL, 8.8 mmol) 
and DMF (30 mL). The resulting solution was stirred at room temperature 
for 2 hours until completion. After solvent evaporation, the crude was 
dissolved in CHCl3 (40 mL) and washed with water (3 x 20 mL) and brine 
 
 
 
 
 
 
(20 mL). The organic layer was dried over MgSO4 and concentrated in 
vacuo. The crude solid was purified by column chromatography on silica 
gel eluted with CHCl3/MeOH (100:1). A final recrystallization using 
acetonitrile yielded iC2Alk2 as a white solid; m. p. 181-182 ºC (0.67 g, 35%). 
1H NMR (300 MHz, CDCl3): δ = 7.98 (s, 1H, H6), 5.19 (bs, 2H, NH2), 4.06 
(q, J = 7.3 Hz, 2H, N1CH2CH3), 1.35 (t, J = 7.3 Hz, 3H, CH3) ppm. 13C NMR 
(75 MHz, CDCl3): δ = 159.4, 158.9, 155.2, 38.5, 29.7, 12.1 ppm. HRMS 
(ESI+): Calculated for C6H9N3OI: 265.9784 [M+H]+. Found: 265.9786 
[M+H]+. 
Standard Procedure C for the carbonyl group protection of the 
guanine derivatives. In a double neck round-bottomed flask, equipped 
with a basic reflux set-up and a magnetic stirrer, activated NaH (4 eq) was 
placed under argon. Dry solvent (indicated in each case) was added and 
the mixture was stirred. Then, 2-trimethylsilylethanol (2 eq) was added 
dropwise and the mixture was stirred under reflux for 2.5 hours. The 
mixture was then allowed to cool down to room temperature and the 
nucleobase (1 eq) was added carefully. The resulting mixture was stirred 
under reflux overnight until the reaction was completed, which was 
monitored by TLC. Work-up and purification methods are indicated in each 
case. 
Synthesis of the guanine derivatives.  
2-amino-6-(2-(trimethylsilyl)ethoxy)-purine (G7):[29] G7 was prepared 
following Standard Procedure C using NaH (118.3 mmol, 2.8 g) and dry 
dioxane (125 mL). Then, 2-trimethylsilylethanol (8.5 mL, 59.2 mmol) was 
added dropwise. Later, 2-amino-6-chloropurine (5.0 g, 29.6 mmol) was 
added. The reaction was completed overnight. The reaction mixture was 
concentrated in vacuo, dissolved in water (100 mL) and washed with ether 
(2 x 50 mL). Acetic acid was added to the aqueous phase until pH 6 and 
the resulting solid was filtered. The crude solid was dried and passed 
through a silica plug eluted with CHCl3/MeOH (10:1). A final 
recrystallization in MeOH/water afforded G7 as a white solid; m. p. 184-
185 ⁰C (2.9 g, 48% yield). 1H NMR (300 MHz, DMSO-d6): δ = 12.36 (bs, 
1H, N9H), 7.77 (s, 1H, H8), 6.15 (bs, 2H, NH2), 4.49 (t, J = 7.0 Hz, 2H, 
OCH2CH2TMS), 1.13 (t, J = 7.0 Hz, 2H, OCH2CH2TMS), 0.07 (s, 9H, 
Si(CH3)3) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 159.9, 159.6, 156.0, 
138.4, 113.0, 63.3, 17.1, -1.3 ppm. HRMS (ESI+): Calculated for 
C10H18N5OSi: 252.1275 [M+H]+. Found: 252.1299 [M+H]+. 
Standard Procedure D for the bromination reaction of the purine 
derivatives. To a solution of the nucleobase (1 eq) in a solvent (indicated 
in each case), NBS (1.1 eq) was added over a period of time (indicated in 
each case). The reaction mixture was stirred for a period of time (indicated 
in each case) at room temperature until the reaction was completed, which 
was monitored by TLC. Work-up and purification methods are indicated in 
each case. 
2-amino-8-bromo-6-(2-(trimethylsilyl)ethoxy)-purine (G6): G6 was 
prepared following Standard Procedure D. G7 (0.10 g, 0.4 mmol) was 
dissolved in acetonitrile (3 mL) and NBS (0.08 g, 0.4 mmol) was added 
over a period of 30 min. The reaction was completed in 3 h. The mixture 
was then filtered through a filter paper and the filtrate was concentrated 
under reduced pressure. The crude solid was purified by column 
chromatography on silica gel eluted with CHCl3/MeOH (50:1), affording 40 
mg of G6 as a yellow solid (35% yield). 1H NMR (300 MHz, DMSO-d6): δ 
= 13.09 (bs, 1H, N9H), 6.33 (bs, 2H, NH2), 4.47 (t, J = 7.0 Hz, 2H, 
OCH2CH2TMS), 1.11 (t, J = 7.0 Hz, 2H, OCH2CH2TMS), 0.06 (s, 9H, 
Si(CH3)3) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 159.5, 159.8, 156.1, 
121.5, 114.7, 63.6, 40.4, 17.0, -1.3 ppm. HRMS (ESI+): Calculated for 
C10H17N5OSiBr: 330.0380 [M+H]+. Found: 330.0395 [M+H]+. 
2-amino-6-chloro-9-decyl-purine (G5Alk10): G5Alk10 was obtained 
following Standard Procedure A using 2-amino-6-chloropurine (8.0 g, 47 
mmol), K2CO3 (7.8 g, 56.4 mmol), 1-iododecane (12 mL, 56.4 mmol) and 
DMF (110 mL). After solvent evaporation, the crude solid was purified by 
column chromatography on silica gel eluted with CHCl3/MeOH (50:1). 
G5Alk10 was obtained as a white solid (12.4 g, 85%). 1H NMR (300 MHz, 
DMSO-d6): δ = 8.13 (s, 1H, N8H), 6.87 (bs, 2H, C2NH2), 4.02 (t, J = 7.0 Hz, 
2H, N9CH2C9H19), 1.8-1.6 (m, 2H, N9CH2CH2C8H17), 1.3-1.1 (m, 14H, 
N9C2H4C7H14CH3), 0.84 (t, J = 7.0 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ = 159.7, 154.0, 149.3, 143.2, 123.4, 43.0, 31.2, 28.9, 28.8, 
28.6, 28.4, 25.9, 22.0, 13.9 ppm. HRMS (ESI+): Calculated for C15H25N5Cl: 
310.1793 [M+H]+. Found: 310.1801 [M+H]+. 
2-amino-6-chloro-9-ethyl-purine (G5Alk2):[26] G5Alk2 was obtained 
following Standard Procedure A using 2-amino-6-chloropurine (3.0 g, 17.7 
mmol), K2CO3 (2.9 g, 21.2 mmol), 1-iodoethane (1.7 mL, 21.2 mmol) and 
DMF (60 mL). After solvent evaporation, the crude solid was purified by 
column chromatography on silica gel eluted with CHCl3/MeOH (50:1). 
G5Alk2 was obtained as a white solid (2.6 g, 74%). 1H NMR (300 MHz, 
DMSO-d6): δ = 8.14 (s, 1H, N8H), 6.91 (bs, 2H, C2NH2), 4.07 (q, J = 7.3 
Hz, 2H, N9CH2CH3), 1.36 (t, J = 7.3 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ = 159.7, 153.9, 149.3, 142.9, 123.4, 38.2, 14.9 ppm. HRMS 
(ESI+): Calculated for C7H9N5Cl: 198.0540 [M+H]+. Found: 198.0542 
[M+H]+. 
2-amino-9-(3,4,5-tris(dodecyloxy)benzyl)-6-chloro-purine (G5Bn3): A 
suspension of 2-amino-6-chloropurine (2.0 g, 11.79 mmol) and K2CO3 (1.9 
g, 14.15 mmol) in dry DMF (130 mL) was stirred at 40 ºC for 30 min. Then 
1-(bromomethyl)-3,4,5-tris(dodecyloxy)benzene (10.3 g, 14.15 mmol) was 
added and the mixture was heated at 40 ºC overnight. The solvent was 
removed under reduced pressure and the crude was purified by column 
chromatography eluted with cyclohexane/AcOEt (4:1), obtaining G5Bn3 as 
a white solid; m. p. 92-94 ⁰C (4.6 g, 48%). 1H NMR (300 MHz, CDCl3): δ = 
7.70 (bs, 1H, H8), 6.43 (s, 2H, Ar-2,6), 5.34 (bs, 2H, C2NH2), 5.10 (s, 2H, 
N9CH2), 3.90 (q, J = 7.0 Hz, 6H, OCH2), 1.72 (m, 6H, OCH2CH2), 1.55-
1.05 (m, 60H, OCH2CH2(CH2 )9CH3), 0.86 (t, J = 6.6 Hz, 9H, O(CH2)11CH3) 
ppm. 13C NMR (75 MHz, CDCl3): δ = 159.3, 154.0, 153.7, 151.4, 142.3, 
138.5, 129.9, 125.2, 106.6, 77.2, 73.6, 69.4, 47.6, 32.0, 30.4, 29.84, 29.80, 
29.74, 29.52, 29.47, 26.2, 22.8, 14.2 ppm. HRMS (ESI+): Calculated for 
C48H83ClN5O3: 812.6178 [M+H]+. Found: 812.6206 [M+H]+. 
2-amino-9-decyl-6-(2-(trimethylsilyl)ethoxy)-purine (G4Alk10):[30] 
G4Alk10 can be obtained following Standard Procedure A using G7 (1.5 g, 
6.0 mmol), K2CO3 (1.0 g, 7.2 mmol), 1-iododecane (1.5 mL, 7.2 mmol) and 
DMF (20 mL). The reaction was completed in 8 h. After solvent evaporation, 
the crude solid was purified by column chromatography on silica gel eluted 
with CHCl3/MeOH (100:1). G4Alk10 was obtained as a white solid (0.97 g, 
42%). G4Alk10 can also be obtained following Standard Procedure C using 
NaH (0.19 g, 0.7 mmol) and 2-trimethylsilylethanol (0.15 mL, 1.0 mmol) in 
dry THF (5 mL).  Then, G5Alk10 (0.16 g, 0.5 mmol) was added. The reaction 
was completed overnight. The reaction mixture was concentrated in vacuo, 
dissolved in ethyl acetate (20 mL) and washed with water (3 x 10 mL). The 
organic layer was dried over MgSO4 and concentrated in vacuo. The crude 
solid was purified by column chromatography on silica gel eluted with 
CHCl3/hexane (5:1), affording G4Alk10 as a white solid (71 mg, 35% yield). 
1H NMR (300 MHz, DMSO-d6): δ = 7.82 (s, 1H, H8), 6.28 (bs, 2H, NH2), 
4.49 (m, 2H, OCH2CH2TMS’), 3.97 (t, J = 7.2 Hz, 2H, N9CH2C9H19), 1.8-
 
 
 
 
 
 
1.6 (m, 2H, N9CH2CH2C8H17), 1.3-1.1 (m, 2H, N9C2H4C7H14CH3), 1.1-1.0 
(m, 2H, OCH2CH2TMS), 0.84 (t, J = 7.1 Hz, 3H, CH3), 0.06 (s, 9H, 
Si(CH3)3) ppm. 13C NMR (75 MHz, CDCl3): δ = 161.4, 159.2, 153.9, 139.1, 
115.8, 64.8, 43.5, 31.8, 29.8, 29.44, 29.40, 29.2, 29.0, 26.6, 22.6, 17.6, 
14.0, 1.41 ppm. HRMS (ESI+): Calculated for C20H38N5OSi: 392.2840 
[M+H]+. Found: 392.2849 [M+H]+. 
2-amino-6-(2-(trimethylsilyl)ethoxy)-9-ethyl-purine (G4Alk2):[30] G4Alk2 
can be obtained following Standard Procedure A using G7 (1.0 g, 3.9 
mmol), K2CO3 (0.6 g, 4.7 mmol), 1-iodoethane (0.4 mL, 4.7 mmol) and 
DMF (20 mL). The reaction was completed in 8 h. After solvent evaporation, 
the crude solid was purified by column chromatography on silica gel eluted 
with CHCl3/MeOH (50:1). G4Alk2 was obtained as a white solid (0.35 g, 
32%). G4Alk2 can also be obtained following Standard Procedure C using 
NaH (0.86 g, 35.8 mmol) and 2-trimethylsilylethanol (2.6 mL, 17.9 mmol) 
in dry THF (50 mL). Then, G5Alk2 (1.77 g, 9.0 mmol) was added. The 
reaction was completed overnight. The reaction mixture was concentrated 
in vacuo, dissolved in CHCl3 (50 mL), washed with ether (30 mL) and then 
with water (3 x 30 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo. The crude solid was purified by column 
chromatography on silica gel eluted with CHCl3/hexane (100:1), affording 
G4Alk2 as a white solid (633 mg, 25% yield). 1H NMR (300 MHz, CDCl3): δ 
= 7.60 (s, 1H, H8), 4.77 (bs, 2H, NH2), 4.6-4.5 (m, 2H, OCH2CH2TMS), 
4.10 (q, J = 7.0 Hz, 2H, N9CH2CH3), 1.48 (t, J = 7.0 Hz, 3H, CH3), 1.3-1.2 
(m, 2H, OCH2CH2TMS), 0.09 (s, 9H, Si(CH3)3) ppm. 13C NMR (75 MHz, 
CDCl3): δ = 162.6, 160.9, 155.0, 140.0, 116.8, 66.0, 39.7, 18.9, 16.7, 0.0 
ppm. HRMS (ESI+): Calculated for C12H22N5OSi: 280.1588 [M+H]+. Found: 
280.1586 [M+H]+. 
2-amino-6-(2-(trimethylsilyl)ethoxy)-9-(3,4,5-tris(dodecyloxy)benzyl)-
purine (G4Bn3): G4Bn3 was obtained following Standard Procedure A using 
NaH (800 mg, 33.37 mmol), 2-(trymethylsilyl)ethanol (1.2 mL, 8.14 mmol) 
and G5Bn3 (3.4 g, 4.17 mmol) in dry dioxane (60 mL). The mixture was 
refluxed overnight until the reaction was completed. The resulting mixture 
was concentrated in vacuo and purified by column chromatography on 
silica gel eluted with cyclohexane/AcOEt (4:1), affording G4Bn3 as a white 
solid (2.23 g, 62%). 1H NMR (300 MHz, CDCl3): δ = 7.55 (s, 1H, H8), 6.45 
(s, 2H, Ar-2,6), 5.12 (s, 2H, N9CH2), 5.02 (bs, 2H, C2NH2), 4.74-4.39 (m, 
2H, C6OCH2), 4.03-3.68 (m, 6H, OCH2), 1.88-1.55 (m, 6H, OCH2CH2), 
1.56-1.11 (m, 62H, OCH2CH2(CH2)9CH3), 1.01-0.77 (m, 9H, O(CH2)11CH3), 
0.09 (s, 9H, Si(CH3)3) ppm. 13C NMR (75 MHz, CDCl3): δ = 161.7, 159.6, 
139.2, 138.3, 130.8, 115.8, 106.5, 77.2, 73.6, 69.4, 65.1, 47.2, 32.1, 30.5, 
29.84, 29.78, 29.5, 26.2, 22.8, 17.8, 14.2, -1.3 ppm. HRMS (ESI+): 
Calculated for C53H96N5O4Si: 894.7226 [M+H]+. Found: 894.7217 [M+H]+. 
2-amino-8-bromo-9-decyl-6-(2-(trimethylsilyl)ethoxy)-purine (G3Alk10): 
G3Alk10 was obtained following Standard Procedure D using G4Alk10 (0.63 
g, 2.3 mmol) in CCl4 (10 mL) and NBS (0.44 g, 2.5 mmol), added over a 
period of 30 min. The reaction mixture was completed 3 h. The crude 
mixture was filtered through a filter paper and the filtrate was concentrated 
under reduced pressure. The crude solid was then purified by column 
chromatography on silica gel eluted with CHCl3/hexane (100:1), affording 
0.87 g of G3Alk10 (80% yield). 1H NMR (300 MHz, DMSO-d6): δ = 6.48 (bs, 
2H, NH2), 4.48 (m, 2H, OCH2CH2TMS), 3.97 (t, J = 7.2 Hz, 2H, 
N9CH2C9H19), 1.8-1.6 (m, 2H, OCH2CH2C8H17), 1.4-1.1 (m, 14H, 
OC2H4C7H14CH3), 1.1-1.0 (m, 2H, OCH2CH2TMS), 0.84 (t, J = 6.7 Hz, 3H, 
N9C9H19CH3), 0.06 (s, 9H, Si(CH3)3) ppm. 13C NMR (75 MHz, CDCl3): δ = 
160.1, 159.0, 154.7, 135.2, 116.0, 65.0, 44.1, 31.9, 29.7, 29.5, 29.4, 29.3, 
29.1, 26.5, 22.7, 17.6, 14.1, 1.42 ppm. HRMS (ESI+): Calculated for 
C20H37N5OSiBr: 470.1945 [M+H]+. Found: 470.1941 [M+H]+. 
2-amino-8-bromo-6-(2-(trimethylsilyl)ethoxy)-9-ethyl-purine (G3Alk2): 
G3Alk2 was obtained following Standard Procedure D using G4Alk2 (0.63 g, 
2.3 mmol) in CCl4 (10 mL) and NBS (0.44 g, 2.5 mmol), added over a 
period of 30 min. The reaction mixture was completed in 4 h. The crude 
mixture was filtered through a filter paper and the filtrate was concentrated 
under reduced pressure. The crude solid was then purified by column 
chromatography on silica gel eluted with CHCl3/hexane (100:1), affording 
0.60 g of G3Alk2 as a white solid (72% yield). 1H NMR (300 MHz, DMSO-
d6): δ = 6.48 (bs, 2H, NH2), 4.48 (m, 2H, OCH2CH2TMS), 4.02 (q, J = 7.1 
Hz, 2H, N9CH2CH3), 1.26 (t, J = 7.2 Hz, 3H, CH3), 1.11 (m, 2H, 
OCH2CH2TMS), 0.06 (s, 9H, Si(CH3)3) ppm. 13C NMR (75 MHz, CDCl3): δ 
= 159.8, 159.2, 154.5, 123.7, 114.1, 63.8, 55.6, 17.0, 14.4, -1.3 ppm. 
HRMS (ESI+): Calculated for C12H21N5OSiBr: 358.0693 [M+H]+. Found: 
358.0693 [M+H]+. 
Standard Procedure E for the iodination reaction of the guanine 
derivatives. To a solution of the nucleobase (1 eq) in THF (volume 
indicated in each case) was added a solution of LDA freshly prepared from 
diisopropylamine (7.5 eq) and nBuLi (2,5 M, 5.0 eq) in THF (volume 
indicated in each case) at -78 °C. After 4 h, a solution of I2 (3.0 eq) in THF 
(volume indicated in each case) was added and the mixture was stirred at 
-78 °C until the reaction was completed, which was monitored by TLC. The 
mixture was left to warm up to 0 °C, followed by hydrolysis with NH4Cl (sat). 
The water phase was separated and extracted with DCM. The combined 
organic layers were concentrated under reduced pressure, dissolved in 
DCM and washed with Na2S2O3 (sat), NaHCO3 (sat) and brine. The organic 
layer was then dried over MgSO4 and concentrated in vacuo. Purification 
methods are indicated in each case. 
2-amino-8-iodo-6-(2-(trimethylsilyl)ethoxy)-9-(3,4,5-
tris(dodecyloxy)benzyl)-purine (G2Bn3): Following Standard Procedure 
E, LDA was prepared from diisopropyl amine (1.6 mL, 11.82 mmol) and a 
2.5 M nBuLi solution in THF (7.88 mL, 7.88 mmol) in THF (21 mL). The 
mixture was stirred at 0 ºC for 45 min, cooled at -78 ºC and then, a solution 
of G4Bn3 (1.41 g, 1.58 mmol) in THF (21 mL) was added via cannula. The 
resulting mixture was stirred at -78 ºC for 5 h. A solution of I2 (1.19 g, 4.7 
mmol) in THF (10 mL) was added. Once the reaction was completed, 
saturated NH4Cl (10 mL) was added to the mixture and the system was 
allowed to slowly reach room temperature. The phases were separated 
and the aqueous phase was extracted with CH2Cl2 (3 x 15 mL). The 
combined organic layer was washed with Na2S2O3 (sat) (1 x 30mL), 
NaHCO3 (sat) (1 x 30 mL) and brine (1 x 30 mL). The organic layer was 
dried over MgSO4 and the solvent was evaporated. The resulting solid was 
purified by column chromatography eluted with cyclohexane/AcOEt (5:1) 
to afford G2Bn3 as a white solid; m. p. 77-79 ⁰C (977 mg, 60%). 1H NMR 
(300 MHz CDCl3): δ = 6.46 (s, 2H, Ar-2,6), 5.07 (s, 2H, N9CH2), 5.00 (s, 
2H, C2NH2), 4.59-4.43 (m, 2H, C6OCH2), 4.01-3.72 (m, 6H, OCH2), 1.70 
(q, J = 6.9 Hz, 6H, OCH2CH2), 1.24 (d, J = 5.8 Hz, 63H, 
OCH2CH2(CH2)9CH3), 0.99-0.73 (m, 9H, O(CH2)11CH3), 0.05 (d, J = 1.3 Hz, 
9H, Si(CH3)3) ppm. 13C NMR (75 MHz, CDCl3): δ = 160.0, 159.3, 155.0, 
153.2, 137.9, 130.5, 118.5, 106.2, 97.0, 73.3, 69.1, 65.0, 48.5, 31.9, 30.3, 
29.68, 29.65, 29.62, 29.60, 29.58, 29.59, 29.53, 29.4, 29.3, 26.0, 22.6, 
17.6, 14.0, -1.5 ppm. HRMS (ESI+): Calculated for C53H94IN5O4Si: 
1020.6192 [M*+H]+. Found: 1020.6210 [M*+H]+. 
9-decyl-8-ethynyl-guanine (G1Alk10): G1Alk10 was prepared following 
Standard Procedure B. G3Alk10 (2.3 g, 4.9 mmol), Pd(PPh3)2Cl2 (68.6 mg, 
0.10 mmol) and CuI (9.3 mg, 0.05 mmol) were dissolved in the THF/NEt3 
mixture (20 mL). Then TMSA (1.80 mL, 9.8 mmol) was added. The 
reaction was completed in 12 h. Then, the reaction mixture was 
 
 
 
 
 
 
concentrated under reduced pressure, dissolved in THF (30 mL) and 
TBAF·3H2O (3.4 g, 10.8 mmol) was added. After solvent evaporation the 
dark brown oil was purified by column chromatography on silica gel eluted 
with CHCl3/MeOH (30:1). G1Alk10 was obtained as a light yellow solid; m. 
p. > 250 ºC (1.1 g, 70%). 1H NMR (300 MHz, DMSO-d6): δ = 10.68 (bs, 1H, 
N1H), 6.59 (bs, 2H, NH2), 4.70 (s, 1H, C≡CH), 3.97 (t, J = 6.9 Hz, 2H, 
N9CH2C9H19), 1.8-1.6 (m, 2H, N9CH2CH2C8H17), 1.3-1.1 (m, 14H, 
N9C2H4C7H14CH3), 0.83 (t, J = 6.9 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ = 156.2, 84.8, 73.6, 42.7, 31.2, 28.85, 28.78, 28.6, 28.4, 25.8, 
22.0, 13.9 ppm. HRMS (ESI+): Calculated for C17H26N5O: 316.2131 
[M+H]+. Found: 316.2146 [M+H]+. 
9-ethyl-8-ethynyl-guanine (G1Alk2): G1Alk2 was prepared following 
Standard Procedure B. G3Alk2 (0.57 g, 1.6 mmol), Pd(PPh3)2Cl2 (22.0 mg, 
0.03 mmol) and CuI (3.0 mg, 0.02 mmol) were dissolved in the THF/NEt3 
mixture (15 mL). Then TMSA (0.6 mL, 3.2 mmol) was added. The reaction 
was completed in 8 h. Then, the reaction mixture was concentrated under 
reduced pressure, dissolved in THF (20 mL) and TBAF·3H2O (1.1 g, 3.5 
mmol) was added. After solvent evaporation the dark brown oil was 
purified by column chromatography on silica gel eluted with CHCl3/MeOH 
(10:1). G1Alk2 was obtained as a light yellow solid; m. p. > 250 ºC (270 mg, 
83%).  1H NMR (300 MHz, DMSO-d6): δ = 10.71 (bs, 2H, NH1), 6.61 (bs, 
2H, NH2), 4.71 (s, 1H, C≡CH), 4.01 (q, J = 7.0 Hz, 2H, N9CH2CH3), 1.27 (t, 
J = 7.0 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 156.2, 154.2, 
150.7, 128.8, 116.5, 84.8, 73.4, 37.7, 14.8. HRMS (ESI+): Calculated for 
C9H10N5O: 204.0879 [M+H]+. Found: 204.0878 [M+H]+. 
9-(3,4,5-tris(dodecyloxy)benzyl)-8-ethynyl-guanine (G1Bn3): G1Bn3 was 
prepared following Standard Procedure B for a Sonogashira coupling 
reaction. G2Bn3 (977 mg, 0.95 mmol), Pd(PPh3)2Cl2 (13.3 mg, 0.019 mmol) 
and CuI (1.8 mg, 0.0095 mmol) were dissolved in the THF/NEt3 mixture 
(10 mL). Then TMSA (0.7 mL, 0.67 mmol) was added and the mixture was 
stirred at 40 ºC for 24 h. Once the reaction was completed, the solvent was 
evaporated in vacuo. TBAF·3H2O (659 mg, 2.09 mmol) was added over a 
solution of the crude in THF (10 mL). The residue was purified by column 
chromatography on silica gel eluted with CHCl3/MeOH (100:1). A final 
recrystallization using CHCl3/MeCN yielded G1Bn3 as a light brown solid; 
m. p. 148-149 ⁰C (598 mg,77%). 1H NMR (300 MHz, CDCl3): δ = 11.81 
(bs, 1H, N1H), 6.64 (bs, 2H, C2NH-H), 6.54 (s, 2H, Ar-2,6), 5.13 (s, 2H, 
N9CH2), 3.89 (t, J = 6.4 Hz, 6H, OCH2), 3.37 (s, 1H, C≡CH), 1.72 (m, 6H, 
OCH2CH2), 1.54-1.07 (m, 60H, OCH2CH2(CH2)9CH3), 0.87 (td, J = 6.7, 2.1 
Hz, 9H, O(CH2)11CH3) ppm. 13C NMR (76 MHz, CDCl3): δ = 154.6, 153.3, 
138.1, 130.9, 106.6, 77.3, 73.5, 69.2, 32.1, 30.5, 29.9, 29.8, 29.7, 29.5, 
26.3, 22.8, 14.3 ppm. Calculated for C50H84N5O4: 818.6517 [M+H]+. Found: 
818.6540 [M+H]+. 
9-(3,5-bis(dodecyloxy)benzyl)-8-ethynyl-guanine (G1Bn2): Following 
Standard Procedure A, G6 (288 mg, 0.87 mmol), K2CO3 (144 mg, 1.044 
mmol) and 1-(chloromethyl)-3,5-bis(dodecyloxy)benzene (516 mg, 1.04 
mmol) were dissolved in dry DMF (10 mL) and heated at 40 ºC overnight. 
Once the reaction was completed, the solvent was removed under reduced 
pressure. The resulting crude was passed through a silica plug eluted with 
CHCl3/MeOH (100:1). The residue was dissolved in the THF/NEt3 mixture 
with Pd(Ph3)2Cl2 (12.3 mg, 0.0175 mmol) and CuI (1.7 mg, 0.009 mmol), 
following Standard Procedure B for a Sonogashira coupling. Then, TMSA 
(0.3 mL, 2.33 mmol) was added. The resulting mixture was stirred at 40 ºC 
overnight. Once the reaction was completed, the solvent was removed 
under reduced pressure. The resulting crude was dissolved in THF (10 
mL) and TBAF·3H2O (548 mg, 1.74 mmol) was added. Once the 
deprotection was completed, the solvent was removed under reduced 
pressure and the crude purified by column chromatography eluted with 
CHCl3/MeOH (100:1). G1Bn2 was obtained as a light brown solid; m. p. 88-
89 ⁰C (219.3 mg, 77%). 1H NMR (300 MHz, CDCl3): δ = 11.90 (bs, 1H, 
N1H), 6.57-6.24 (m, 3H, Ar-2,4,6), 5.16 (s, 2H, N9CH2), 3.86 (t, J = 6.5 Hz, 
5H, OCH2), 3.35 (s, 1H, C≡CH), 1.88-1.58 (m, 6H, OCH2CH2), 1.26 (m, 
39H, OCH2CH2(CH2)9CH3), 0.98-0.72 (m, 6H, O(CH2)11CH3) ppm. 13C 
NMR (75 MHz, CDCl3): δ =163.9, 162.6, 155.8, 153.7, 150.3, 138.4, 130.7, 
107.1, 77.2, 73.5, 69.4, 56.3, 52.6, 36.6, 32.0, 31.5, 30.4, 29.84, 29.82, 
29.80, 29.78, 29.75, 29.7, 29.7, 29.5, 29.48, 29.5, 26.2, 22.8, 14.2 ppm. 
HRMS (ESI+): Calculated for C38H60N5O3: 634.4690 [M+H]+. Found: 
634.4688 [M+H]+. 
8-bromo-N2isobutyryllguanine (G12): To a suspensión of N2-
isobutyrylguanine[33] (5.85 g, 26.48 mmol) and AcONa (6.29 g, 52.96 
mmol) in AcOH (70 mL), Br2 (2 mL, 52.96 mmol) was added. The mixture 
was stirred at 80 ºC overnight. Once the reaction was completed, the 
system was allowed to cool to room temperature and the resulting solid 
was filtered and washed with H2O and EtOH. G12 was obtained as a white 
solid (6.37 g, 80%). 1H NMR (300 MHz, DMSO-d6): δ = 13.88 (bs, 1H, N1H), 
12.09 (bs, 1H, N9H), 11.60 (s, 1H, NHCOiPr), 2.75 (sep, J = 6.8 Hz, 1H, 
CHiPr), 1.12 (d, J = 6.8 Hz, 6H, CH3iPr) ppm. 13C NMR (75 MHz, DMSO-
d6): δ =180.0, 154.3, 153.0, 147.2, 39.5, 34.7, 19.0 ppm. HRMS (FAB+): 
Calculated for C9H11BrN5O2: 300.0096 [M+H]+. Found: 300.0092 [M+H]+. 
8-bromo-O6-diphenylcarbamoil-N2-isobutyrylguanine (G11): To a 
suspension of G12 (6.37 g, 21.22 mmol), DMAP (51.53 mg, 0.42 mmol) 
and diphenylcarbamoyl chloride (5.89 g, 42.44 mmol) in CHCl3 (300 mL) 
under argon, DIPEA (5.4 mL, 31.38 mmol) was added. The resulting 
mixture was stirred at reflux overnight. Then, the mixture was filtered and 
the solvent was removed under reduced pressure. The crude was purified 
by column chromatography eluted with CHCl3/MeOH (100:1) obtaining 
G11 as a white solid; m. p. 140-141 ⁰C (8.17 g, 78%). 1H RMN (300 MHz, 
DMSO-d6): δ = 12.16 (bs, 1H, N1H), 11.89 (s, 1H, N9H), 7.51-7.28 (m, 10H, 
Ph), 2.77 (sept, J = 6.9 Hz, 1H, CHiPr), 1.16 (d, J = 6.9 Hz, 6H, CH3iPr) 
ppm. 13C RMN (75 MHz, DMSO-d6): δ = 180.4, 153.2, 150.1, 148.3, 146.8, 
141.1, 139.9, 129.6, 129.4, 128.5, 127.9, 127.9, 126.8, 126.0, 119.9, 118.9, 
79.1, 34.9, 18.9, 18.7 ppm. HRMS (ESI+): Calculated for C22H20N6O3Br: 
495.0774 [M+H]+. Found: 495.0758 [M+H]+. 
8-bromo-9-(2-tertbutylacetyl)-O6-diphenylcarbamoyl-N2-
isobutyrylguanine (G10Es): Following Standard Procedure A, a solution 
of G11 (2.35 g, 4.74 mmol) and K2CO3 (0.8 g, 5.8 mmol) in dry DMF (60 
mL) was stirred for 30 min. Then, tertbutyl-bromoacetate (839 µL, 5.68 
mmol) was added and the resulting mixture was stirred at 40 ºC for 24 h. 
The solvent was evaporated after completion and the residue was 
dissolved in CHCl3 (15 mL). The organic layer was washed with water (2 x 
15 mL) and brine (20 mL) and dried over MgSO4. The solvent was removed 
under reduced pressure, affording G10Es as a white solid; m. p. 102-104 
⁰C (0.81 g, 28%). 1H RMN (300 MHz, CDCl3): δ = 7.75 (s, 1H, NHCOiPr), 
7.49-7.08 (m, 10H, Ph), 4.88 (s, 2H, CH2) 3.24 (sep, J = 6.8 Hz, 1H, CHiPr), 
1.40 (s, 9H, CH3tBu), 1.27 (d, J = 6.8 Hz, 6H, CH3iPr) ppm. 13C RMN (75 
MHz, DMSO-d6): δ = 176.1, 166.2, 158.3, 153.4, 151.8, 147.0, 129.1, 
127.6, 126.9, 125.6, 124.1, 116.8, 82.3, 63.6, 34.9, 27.7, 19.0 ppm. HRMS 
(ESI+): Calculated for C28H30N6O5Br: 609.1455 [M+H]+. Found: 609.1459 
[M+H]+. 
Synthesis of the adenine derivatives.  
2,6-diamino-9-decyl-purine (A4Alk10): A4Alk10 was obtained following 
Standard Procedure A using 2,6-diaminopurine (5.0 g, 33 mmol), K2CO3 
(5.5 g, 40 mmol), 1-iododecane (8.6 mL, 40 mmol) and DMF (100 mL). 
 
 
 
 
 
 
The reaction was completed overnight. After solvent evaporation, the 
crude was dissolved in CHCl3 (200 mL) and washed with water (3 x 100 
mL) and brine (100 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo. The crude solid was purified by column 
chromatography on silica gel eluted with CHCl3/MeOH (50:1). A4Alk10 was 
obtained as a white solid (6.7 g, 69%). 1H NMR (300 MHz, DMSO-d6): δ = 
7.69 (s, 1H, N8H), 6.61 (bs, 2H, C6NH2), 5.75 (bs, 2H, C2NH2), 3.92 (t, J = 
6.7 Hz, 2H, N9CH2C9H19), 1.8-1.6 (m, 2H, N9CH2CH2C8H17), 1.3-1.1 (m, 
14H, N9C2H4C7H14CH3), 0.84 (t, J = 6.5 Hz, 3H, CH3) ppm. 13C NMR (75 
MHz, DMSO-d6): δ = 160.2, 156.1, 151.2, 137.6, 113.2, 42.4, 31.3, 29.3, 
29.0, 28.8, 28.7, 28.6, 26.1, 22.1, 14.0 ppm. HRMS (ESI+): Calculated for 
C15H27N6: 291.2291 [M+H]+. Found: 291.2302 [M+H]+. 
2,6-diamino-9-ethyl-purine (A4Alk2): A4Alk2 was obtained following 
Standard Procedure A using 2,6-diaminopurine (3.0 g, 20 mmol), K2CO3 
(3.3 g, 24 mmol), 1-iodoethane (2 mL, 24 mmol) and DMF (150 mL). The 
reaction was completed overnight. The crude mixture was concentrated 
under reduced pressure and the crude solid was purified by column 
chromatography on silica gel eluted with CHCl3/MeOH (10:1), affording 2.4 
g of A4Alk2 (67% yield).  1H NMR (300 MHz, DMSO-d6): δ = 7.71 (s, 1H, 
N8H), 6.64 (bs, 2H, C6NH2), 5.77 (bs, 2H, C2NH2), 3.97 (q, J = 7.3 Hz, 2H, 
N9CH2CH3), 1.32 (t, J = 7.3 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, DMSO-
d6): δ = 160.2, 156.0, 151.3, 137.0, 113.3, 37.3, 15.3. HRMS (ESI+): 
Calculated for C7H11N6: 179.1039 [M+H]+. Found: 179.1038 [M+H]+. 
2,6-diamino-8-bromo-9-decyl-purine (A3Alk10): A3Alk10 was obtained 
following Standard Procedure D using A4Alk10 (4.9 g, 16.9 mmol) in 
acetonitrile (80 mL) and NBS (3.6 g, 18.6 mmol), which was added over a 
period of 4 h. The reaction was completed overnight. Then, the crude 
mixture was concentrated under reduced pressure and the crude solid was 
purified by column chromatography on silica gel eluted with CHCl3/MeOH 
(30:1), affording 0.8 g of A3Alk10 as an ochre solid; m. p. 140-142 ºC (13% 
yield). 1H NMR (300 MHz, DMSO-d6): δ = 6.77 (bs, 2H, C6NH2), 5.87 (bs, 
2H, C2NH2), 3.90 (t, J = 7.1 Hz, 2H, N9CH2C9H19), 1.68 (m, 2H, 
N9CH2CH2C8H17), 1.3-1.1 (m, 14H, N9C2H4C7H14CH3), 0.82 (t, J = 7.1 Hz, 
3H, CH3) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 160.3, 155.0, 152.7, 
121.0, 113.5, 43.0, 31.2, 28.8, 28.7, 28.6, 28.5, 25.9, 22.0, 13.9 ppm. 
HRMS (ESI+): Calculated for C15H26BrN6: 369.1396 [M+H]+. Found: 
369.1411 [M+H]+. 
2,6-diamino-9-decyl-8-iodo-purine (A2Alk10):[38] Iodine (2.3 g, 9.3 mmol) 
was added to a suspension of H5IO6 (1.4 g, 6.2 mmol) in MeOH (10 mL) 
at room temperature. After 10 min, a solution of A2Alk10 (1.8 g, 6.2 mmol) 
in MeOH (10 mL) was added at room temperature. The reaction mixture 
was stirred at 70 ºC for 5 h. After completion, the mixture was let to cool 
down to room temperature and Na2S2O5 (sat) (10 mL) was added. The 
mixture was extracted in CH2Cl2 (30 mL) and washed with water (20 mL) 
and brine (20 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo. The crude solid was purified by column 
chromatography on silica gel eluted with CHCl3/MeOH (50:1). A2Alk10 was 
obtained as a white solid (1.3 g, 50%). 1H NMR (300 MHz, DMSO-d6): δ = 
6.74 (bs, 2H, C6NH2), 5.81 (bs, 2H, C2NH2), 3.86 (t, J = 7.3 Hz, 2H, 
N9CH2C9H19), 1.7-1.6 (m, 2H, N9CH2CH2C8H17), 1.3-1.1 (m, 14H, 
N9C2H4C7H14CH3), 0.84 (t, J = 6.9 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ = 160.2, 154.8, 152.8, 116.2, 95.8, 44.3, 31.3, 29.1, 28.88, 
28.87, 28.7, 28.6, 26.0, 22.1, 13.9 ppm. HRMS (ESI+): Calculated for 
C15H26IN6: 417.1258 [M+H]+. Found: 417.1275 [M+H]+. 
2,6-diamino-9-ethyl-8-iodo-purine (A2Alk2): A2Alk2 (1.0 g, 5.6 mmol), 
iodine (1.3 g, 2.1 mmol) and H5IO6 (1.3 g, 5.6 mmol) were stirred in DMF 
(30 mL) at 70 ºC for 24 h. After completion, the reaction mixture was 
concentrated in vacuo. The crude was dissolved in CHCl3 (50 mL) and 
washed with Na2S2O5 (sat) (40 mL), water (40 mL) and brine (40 mL). The 
organic layer was dried over MgSO4 and concentrated under reduced 
pressure. The crude solid was purified by column chromatography on silica 
gel eluted with CHCl3/MeOH (10:1). A2Alk2 was obtained as a white solid; 
m. p. 242-243 ºC (0.6 g, 37%). 1H NMR (300 MHz, DMSO-d6): δ = 6.77 
(bs, 2H, C6NH2), 5.87 (bs, 2H, C2NH2), 3.92 (q, J = 7.4 Hz, 2H, N9CH2CH3), 
1.23 (t, J = 7.0 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 160.3, 
154.9, 152.5, 116.3, 95.4, 38.8, 15.0 ppm. HRMS (ESI+): Calculated for 
C7H10N6I: 305.0006 [M+H]+. Found: 305.0001 [M+H]+. 
2,6-diamino-9-decyl-8-ethynyl-purine (A1Alk10): A1Alk10 was prepared 
following Standard Procedure B. A2Alk10 (0.34 g, 0.8 mmol), Pd(PPh3)2Cl2 
(11.4 mg, 0.02 mmol) and CuI (1.5 mg, 0.01 mmol) were dissolved in the 
THF/NEt3 mixture (13 mL). Then TMSA (0.3 mL, 1.6 mmol) was added. 
The reaction was completed in 12 h. The mixture was concentrated under 
reduced pressure, dissolved in THF (15 mL) and TBAF·3H2O (0.3 g, 0.9 
mmol) was added. A1Alk10 was purified by column chromatography on 
silica gel eluted with CHCl3/MeOH: (20:1) affording A1Alk10 as a white solid 
(130 mg, 51%). A1Alk10 can also been obtained following Standard 
Procedure B with A3Alk10 (0.91 g, 2.5 mmol), Pd(PPh3)2Cl2 (36.1 mg, 0.05 
mmol) and CuI (4.9 mg, 0.02 mmol) were dissolved in the THF/NEt3 
mixture (10 mL). Then TMSA (0.9 mL, 5.0 mmol) was added. The reaction 
was completed in 12 h. The mixture was concentrated under reduced 
pressure, dissolved in THF (15 mL) and TBAF·3H2O (0.9 g, 2.8 mmol) was 
added. A1Alk10 was purified by column chromatography on silica gel eluted 
with CHCl3/MeOH: (20:1) affording A1Alk10 as a white solid; m. p. 144-145 
ºC (130 mg, 82%). 1H NMR (300 MHz, DMSO-d6): δ = 6.86 (bs, 2H, C6NH2), 
5.94 (bs, 2H, C2NH2), 4.69 (s, 1H, C≡CH), 3.98 (t, J = 6.9 Hz, 2H, 
N9CH2C9H19), 1.71 (m, 2H, N9CH2CH2C8H17), 1.4-1.1 (m, 14H, 
N9C2H4C7H14CH3), 0.84 (t, J = 6.9 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ = 161.2, 156.1, 151.4, 129.0, 113.1, 84.7, 74.0, 42.4, 31.3, 
28.95, 28.90, 28.7, 28.6, 26.0, 22.1, 13.9 ppm. HRMS (ESI+): Calculated 
for C17H27N6: 315.2291 [M+H]+. Found: 315.2289 [M+H]+. 
2,6-diamino-9-ethyl-8-ethynyl purine (A1Alk2): A1Alk2 was prepared 
following Standard Procedure B. A2Alk2 (0.45 g, 1.5 mmol), Pd(PPh3)2Cl2 
(20.6 mg, 0.03 mmol) and CuI (2.8 mg, 0.01 mmol) were dissolved in the 
THF/NEt3 mixture (35 mL). Then, TMSA (0.4 mL, 3.0 mmol) was added. 
The reaction was completed in 12 h. The mixture was concentrated under 
reduced pressure, dissolved in THF (35 mL) and TBAF·3H2O (0.55 g, 1.65 
mmol) was added. A1Alk2 was purified by column chromatography on silica 
gel eluted with CHCl3/MeOH: (10:1) affording A1Alk2 as a white solid; m. p. 
> 250 ºC (146 mg, 48%). 1H NMR (300 MHz, CDCl3): δ = 5.41 (bs, 2H, 
C6NH2), 4.77 (bs, 2H, C2NH2), 4.18 (q, J = 7.2 Hz, 2H, N9CH2CH3), 3.42 
(s, 1H, C≡CH), 1.42 (t, J = 7.2 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ = 161.2, 156.1, 151.1, 128.4, 113.1, 84.7, 73.9, 37.3, 14.9 
ppm. HRMS (ESI+): Calculated for C9H11N6: 203.1039 [M+H]+. Found: 
203.1040 [M+H]+. 
Synthesis of the isoguanine derivative.  
9-ethyl-8-ethynyl-isoguanine (iG1Alk2):[39a] iG1Alk2 was prepared from 
A2Alk2 (0.15 g, 0.5 mmol) following the same procedure than A1Alk2 but, 
before TMS-deprotection, the crude mixture after the Sonogashira 
coupling was suspended in a 1:1 THF/H2O mixture (18 mL). Then, a 
solution of NaNO2 (0.15 g, 2.2 mmol) in H2O (2 mL) was added. The 
mixture was heated at 50 ºC and a 1:1 AcOH/H2O mixture (0.5 mL) was 
slowly added. The reaction mixture was stirred at 50 ºC for 2 h. Once 
 
 
 
 
 
 
completed, the mixture was let to cool down to room temperature and NH3 
was added until pH 8. The reaction mixture was concentrated under 
reduced pressure. Then, K2CO3 (0.15 g, 1.1 mmol) was added over a 
MeOH (10 mL) solution of the resulting crude solid. The reaction mixture 
was stirred at room temperature for 1 h. until completion. After solvent 
evaporation the crude solid was purified by column chromatography on 
silica gel eluted with CHCl3/MeOH (20:1). iG1Alk2 was obtained as a light 
yellow solid; m. p. > 250 ºC (81 mg, 73%). 1H NMR (300 MHz, DMSO-d6): 
δ = 11.0 (bs, 1H, N3H), 7.90 (bs, 2H, NH2), 4.80 (s, 1H, C≡CH),  3.97 (q, J 
= 7.2 Hz, 2H, N9CH2CH3), 1.26 (t, J = 7.2 Hz, 3H, CH3) ppm. 13C NMR (75 
MHz, DMSO-d6): δ = 130.3, 85.5, 79.2, 73.2, 56.1, 45.9, 37.5, 14.7, 8.7 
ppm. HRMS (ESI+): Calculated for C9H10N5O: 204.0879 [M+H]+. Found: 
204.0879 [M+H]+. 
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